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1 Introduction 
1.1 Functional specialization of the immune 
system 
The human body has developed a wide range of defense mechanisms in order to survive in a 
hostile environment. These mechanisms protect us against attacks from infectious agents, 
such as bacteria, viruses, fungi and parasites, and collectively constitute what is known as the 
immune system (Medzhitov, 2007;Litman et al., 2010). The immune system is crucial to 
human health in preventing pathogenic organisms from entering the body and causing harm to 
cells and tissues. In addition, it plays an important role in identifying and eliminating nascent 
tumors (Zitvogel et al., 2006). If the immune system were to fail, even minor pathogenic 
threats would pose a fatal risk (Medzhitov, 2007;Litman et al., 2010). 
1.1.1 General overview of the innate and adaptive immune systems 
The vertebrate immune system includes two functional divisions; the innate – or natural – 
immune system and the adaptive immune system, which is sometimes referred to as acquired 
or specific. While the innate immune system may counter an infection in its nascence through 
preformed cells and factors, the adaptive immune system has a slow but powerful onset and is 
responsible for clearing established infections. Both levels of protection involve a variety of 
blood-borne immune cells known as leukocytes or white blood cells. Whereas the key players 
of the innate immune system are phagocytes such as granulocytes, macrophages and dendritic 
cells, the adaptive immune system relies on the actions of B- and T cells. The B- and T cells, 
also known as B- and T lymphocytes, originate from common lymphoid progenitor cells in 
the bone marrow and are responsible for all of the three hallmarks of adaptive immunity: 
specificity, immunological memory, and enhanced secondary immune responses. 
The bone marrow and thymus are termed the primary lymphoid organs. This is where the 
lymphoid progenitor cells differentiate into mature B- and T cells (Ceredig et al., 2009;Miller, 
2011) (Figure 1). The secondary lymphoid organs include the lymph nodes and lymphatic 
structures present in the mucosa and the gut, as well as the spleen. These are nodes in the 
lymphatic circulation, which serve to capture antigens brought to them through lymph or 
blood and present them to circulating lymphocytes. An adaptive immune response is initiated 
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when a lymphocyte encounters its cognate antigen in one of these secondary lymphoid tissues 
(Figure 1), as detailed later. However, the time required for such a response to mount is 
significant, and while the lymphoid activation and maturation proceeds, the body relies on 
innate immune mechanisms for its protection (Medzhitov, 2007). As opposed to adaptive 
immunity, the innate immune response is initiated at the site of infection with preformed cells 
and immune factors, thus responding without delay. Importantly, cues from the innate 
immune response serve to direct and influence the nature of the resulting adaptive immune 
response elicited in the secondary lymphoid organs against the same infection (Iwasaki and 
Medzhitov, 2010;Medzhitov, 2007). 
 
Figure 1. Overview of B- and T cell production and maturation in primary lymphoid organs 
and their migration and recirculation to secondary lymphoid organs.  The B- and T cells originate 
from pluripotent stem cells in the bone marrow. In contrast to B cells (red), which complete their 
maturation processes in the bone marrow, T cell precursors leave the bone marrow at an early stage and 
migrate to the thymus where they differentiate into mature T cells (blue). After maturation, B- and T 
cells are transported via the blood to secondary lymphoid organ such as the spleen and lymph nodes, in 
search for their cognate antigen. From the secondary lymphoid organs, mainly T cells, but also a fraction 
of B cells, recirculate back to the blood via the lymph and the thoracic duct, as depicted in the figure. 
Adapted from (Miller, 2011). 
The innate defense mechanisms include complement proteins and inflammatory cytokine 
responses, as well as innate immune cells such as macrophages, neutrophils and natural killer 
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(NK) cells. The macrophages and neutrophils are phagocytes, which destruct invading 
pathogens by engulfing and digesting them along with tissue debris and dead cells. The NK 
cells are small granular cytotoxic lymphocytes that migrate into infected tissues in response to 
inflammatory cytokines and kill infected cells without prior sensitization (Sun and Lanier, 
2011). As opposed to adaptive immunity, innate immunity does not produce a specific 
immunological memory of the infection. 
The specificity and memory of adaptive immunity arise from the recombination of genes 
coding for segments of the B- and T cell antigen receptors (Brack et al., 1978;Gellert, 
2002;Tonegawa, 1983). The recombination relies on a recombinase complex of two 
lymphoid-specific proteins encoded by the recombination-activating gene 1 (RAG1) and 
RAG2 that serves to generate antigen receptors with a multitude of specificities (McBlane et 
al., 1995;Schatz et al., 1989;Oettinger et al., 1990). Once the antigen receptor recognizes its 
cognate antigen in the context of sufficient costimulation (see below), the intracellular 
signaling emanating from the activated receptor triggers proliferation and differentiation of 
the lymphocyte, resulting in a clone of lymphocytes specific for the same antigen. This 
process is known as clonal selection and results in the generation of short-lived effector cells 
and long-lived memory cells. As described later on, the memory cells are capable of mounting 
an enhanced secondary immune response if the same antigen is encountered again (Ahmed 
and Gray, 1996;Zinkernagel et al., 1996). 
1.1.2 Innate immune mechanisms regulate adaptive immunity 
Sufficient costimulation is a prerequisite for adaptive immunity. This involves presenting the 
pathogen in the context of an antigen–major histocompatibility complex (MHC) on the 
surface of an antigen-presenting cell (APC) such as dendritic cells (DC), macrophages and B 
cells (Davis and Bjorkman, 1988;Neefjes et al., 2011). In addition to the costimulatory signals 
afforded by the MHC molecules, other cell-bound and soluble signals play an important role 
in directing adaptive immunity. Such signals include the "danger signals" elicited by the 
innate immune system in response to foreign materials (Matzinger, 2002). Innate immune 
cells respond to dangers through a set of pattern recognition receptors (PRRs) that recognize 
different types of pathogens through conserved pathogen-associated molecular patterns 
(PAMPs) – such as lipopolysaccharides and mannose – that are shared by bacteria, viruses 
and parasites (Iwasaki and Medzhitov, 2010;Medzhitov, 2007). The PRRs are subdivided into 
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secreted, transmembrane and cytosolic pattern recognition receptors, among which the best 
characterized receptors are the transmembrane PRRs of the Toll-like receptor (TLR) family. 
Detection of a viral particle or a microbial cell component through PRRs expressed on the 
surface of an APC induces endocytosis or phagocytosis of the pathogen, resulting in 
presentation of pathogen-derived antigens to T cells in the context of MHC molecules. 
Simultaneously, the APC up-regulates its expression of costimulatory molecules and begins 
secreting various cytokines with the aim of priming nearby T cells for activation. The nature 
of the pathogen determines the PRRs it activates, which in turn dictates the immune response 
elicited against it (Iwasaki and Medzhitov, 2010;Medzhitov, 2007). Thus, antigens derived 
from invading pathogens are discriminated from self-antigens in part by the expression of 
stimulatory coreceptors that results from the activation of PRRs. 
DCs are the archetypal professional APC and superior to other APCs in activating naive T 
cells (Steinman, 2008;Pulendran and Ahmed, 2006). They are strategically placed in both 
lymphoid and non-lymphoid sites as immune sentinels, and perform sampling of the 
microenvironment by phagocytosing extracellular material. The recognition of pathogens 
through PRRs leads to the activation of immature DCs. This results in more efficient 
endocytosis, followed by secretion of inflammatory cytokines and acquisition of migratory 
properties (Iwasaki and Medzhitov, 2010;Medzhitov, 2007). The activated DCs migrate from 
the infected tissues to draining lymph nodes where they mature into cells capable of 
presenting pathogen-derived antigens to circulating lymphocytes and initiating adaptive 
immune responses (Cavanagh and von Andrian, 2002;Randolph et al., 2008). When the 
presented antigen is recognized by a cognate T cell, a signal initiated by the interaction of the 
intercellular adhesion molecule 1 (ICAM1) on the APC with the lymphocyte function-
associated antigen 1 (LFA1; also termed L2 integrin) on the T cell induces a stable 
interaction between the cells that consequently leads to retention of the T cell (Dustin and 
Springer, 1989;Pribila et al., 2004;Dustin et al., 1997). This interaction, which is referred to as 
either the supramolecular activation cluster (SMAC) (Monks et al., 1998) or the 
immunological synapse (Grakoui et al., 1999), is essential for the activation of naive T cells 
(Dustin, 2009). Multiple signaling pathways are initiated at this contact site, all of which 
influence the fate of the T cell. The final outcome depends on the quality, strength, and 
duration of the T cell–APC interaction, resulting in proliferation, anergy, or apoptosis (Iezzi et 
al., 1998;Huppa et al., 2003;Gett et al., 2003). 
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1.1.3 Immunological memory 
A fundamental feature of the adaptive immune system is the capacity to form immunological 
memory, resulting in long-lasting protection from recurrent infections by the same pathogen 
(Dutton et al., 1998;Gray, 1993;Dutton et al., 1999;Wherry et al., 2003). Immunological 
memory depends on the generation of memory B- and T cells as well as long-lived plasma 
cells that continuously secrete high-affinity neutralizing antibodies (Sallusto et al., 2010). 
Memory B- and T cells develop from naive progenitor cells throughout the course of a 
primary infection. These memory cells remain even after the infection has been cleared 
(Figure 2). 
Both naive and memory T cells are long-lived cells that circulate the blood and lymph 
systems in a resting state. However, in response to a secondary challenge by the same 
pathogen, resting memory T cells differentiate more rapidly into effector T cells and perform 
their effector functions faster than their naive counterparts. Accordingly, memory T cells offer 
a more potent and efficient immune response in the early phases of the secondary infection, 
when the amounts of antigen are limited. This provides enhanced protection to the host and 
leads directly to reduced disease severity (Ahmed et al., 2009;Harty and Badovinac, 
2008;Jameson and Masopust, 2009;Kaech and Wherry, 2007;Williams and Bevan, 2007). 
As Figure 2 illustrates, the generation of memory T cells occurs in two stages (Salek-
Ardakani and Croft, 2006;Williams and Bevan, 2007). The first phase, called the effector 
phase, is characterized by expansion and differentiation, and usually takes place the second 
week after infection until the pathogen is cleared (Figure 2). Throughout this phase pathogen-
derived antigens are brought to the secondary lymphoid tissues by APCs. Here, naive 
circulating T cells scan the surface of lymph node-resident APCs with their TCRs, and are 
retained by the formation of immunological synapses upon antigen recognition. This initiates 
proliferation and differentiation of the naive T cell into an expanded population of effector T 
cells that migrate to the site of infection. These effector cells are the ones that perform 
specialized T cell functions, such as secretion of cytokines, in order to facilitate the activation 
of B cells (CD4+ T cells) or acquire cytolytic capacity (CD8+ T cells). Although the effector T 
cells are in a highly active state, they require continuous stimulation through the TCR and 
costimulatory receptors (e.g. CD28 and CD2) in order to carry out their immune functions 
(Iezzi et al., 1998). As the levels of antigen diminish, the majority of effector cells enter into 
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apoptosis and the immune response proceeds to a second phase of contraction and generation 
of memory cells (Dooms and Abbas, 2002;Seder and Ahmed, 2003) (Figure 2). 
 
Figure 2. Differentiation of naive CD4+ and CD8+ T cells into effector and memory cells. Naive 
CD4+ T cells first encounter their cognate antigen in the spleen or in a lymph node draining the site of 
infection. Here, they recognize the peptide antigen as bound to MHC class II on an APC, leading to 
clonal expansion of antigen-specific T helper (Th) cells. Naive CD8+ T cells, on the other hand, 
recognize their cognate antigen in the context of MHC class I and generate clones of antigen-specific 
cytotoxic T (Tc) cells, also referred to as cytotoxic T lymphocytes (CTL). The T cell receptor (TCR) 
constitutes the antigen-binding receptor for both lineages. Depending on the nature of the invading agent 
and the cytokines secreted at the site of infection, the clonally expanded and fully differentiated effector 
T cells may acquire different effector functions. The cartoon illustrates the divergence of CD4+ T cells 
into the classical Th1 and Th2 lineages and the differentiation of CD8+ T cells into CTLs in the presence 
of antigens. After the pathogen becomes eliminated, most of the effector cells enter apoptosis, while a 
small fraction of approximately 10% survive and become long-lived memory cells. Adapted from (Salek-
Ardakani and Croft, 2006;Williams and Bevan, 2007;Zhang and Bevan, 2011). 
T cells at different stages of activation may be phenotypically distinguished by their 
expression of different CD45 isoforms. Naive T cells express the CD45RA isoform, whereas 
effector/memory T cells typically express CD45RO (Dutton et al., 1998). CD45 is a 
transmembrane protein tyrosine phosphatase (PTPase) abundantly expressed in all nucleated 
hematopoietic cells (Figure 3). Other than being a phenotypic marker CD45 is also known as 
an important inducer of signaling through the TCR (Desai et al., 1994;Volarevic et al., 
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1993;Hovis et al., 1993;Koretzky et al., 1990). Due to alternative splicing of its extracellular 
domain, the enzyme exists in several isoforms where the largest isoform includes all three 
alternatively spliced exons (CD45RABC) and the smallest contains none (CD45RO) 
(Trowbridge and Thomas, 1994) (Figure 3). As antigen-inexperienced naive T cells become 
activated and differentiate into effector/memory T cells, their CD45 expression switches 
within 3-5 days from the larger CD45RA isoform to the smaller CD45RO isoform (Akbar et 
al., 1988;Birkeland et al., 1989). We took advantage of this alternate splicing in Paper I-II, 
where we used CD45RA and CD45RO as markers to distinguish between naive and 
effector/memory T cells (CD45RA+/CD45RO- and CD45RA-/CD45RO+, respectively). 
 
Figure 3.  The molecular structure of 
CD45. As a result of alternative splicing of 
the extracellular CD45 exons, CD45 comes in 
multiple isoforms. Depicted in this figure is 
the size comparison of the largest 
CD45RABC isoform with the smallest 
CD45RO isoform, and that of the CD4 
coreceptor expressed on the surface of CD4+
T cells. Adapted from (Penninger et al., 2001).
1.1.4 Specialization of the CD4+ effector T cells 
Following antigenic activation, CD4+ T cells may acquire a number of different phenotypes 
and functions. Several lineages of Th cells have been identified, each of which secrete a 
distinct set of cytokines (Zhou et al., 2009;Zhu et al., 2010;O'Shea and Paul, 2010). The 
different Th lineages are thought to fulfill different functions and may have become 
specialized towards particular types of infections. Thus, depending on the type of pathogen 
encountered, the resulting pool of pathogen-specific effector Th cells may be skewed towards 
one or more of the Th lineages. These include, among others, the classical Th1 (Szabo et al., 
2003) and Th2 cells (Ansel et al., 2006), as well as the more recently identified Th17 (Chen et 
al., 2007) and follicular helper T (Tfh) cells (Crotty, 2011;King, 2009) (see Figure 4). 
The cytokine environment in combination with the strength of the antigen–TCR interaction 
dictate the functional fates of activated T cells in a particular infection (Zhou et al., 2009;Zhu 
et al., 2010;O'Shea and Paul, 2010) (Figure 4). Among the many combinations of cytokines 
possible, the pro-inflammatory cytokine interferon  (IFN-), produced by both NK cells and 
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T cells, in combination with interleukin (IL)-12 produced by innate immune cells will 
polarize the Th differentiation towards that of Th1 cells. This process involves activation of 
the transcription factors signal transducer and activator of transcription 4 (Stat4), Stat1 and 
the T box transcription factor T-bet. The cells that belongs to the Th1 lineage are known to be 
important for development of cellular immunity against intracellular microorganisms, and are 
characterized by predominant production of IFN- (Szabo et al., 2003). 
 
Figure 4. The cytokines induced in the microenvironment in response to features of the 
invading pathogen determine the functional fates of the responding T cells. Naive CD4+ T cells 
responding to an infection proliferate and differentiate into effector T cells with helper functions 
specially suited to that infection. Depending on the cytokine milieu, the differentiating CD4+ T cells 
acquire different functions. For instance, in the presence of IFN- and IL-12, the T cell may differentiate 
into and produce cytokines of the Th1 lineage. In the same way, IL-4 facilitates differentiation into Th2 
cells, while IL-6 and TGF- promote differentiation towards Th17 cells. The recently identified Th22 
lineage seems to be favored by the combined secretion of IL-6 and TNF at the site of activation (Duhen 
et al., 2009). Tfh cells represent another recently discovered lineage that appears to result from the 
combined presence of IL-12 and IL-21. In addition, T cells with regulatory capacity (iTregs) may be 
induced from naive T cells in the presence of TGF-, retinoic acid (RA) and IL-2. Finally, it has been 
hypothesized from recent findings that Th2 cells may differentiate into IL-9 producing Th9 cells, 
although this remains to be confirmed. The adaptations described here depend on, but are not restricted 
to, the expression of the following lineage-defining transcription factors: T-bet for Th1, GATA3 for Th2, 
ROR-C for Th17, ROR-C and aryl hydrocarbon receptor (AHR) for Th22 (Trifari et al., 2009), and 
FOXP3 for iTregs. Recent findings indicate a high degree of plasticity and inter-convertability between 
the functionally distinct Th lineages. Arrows in the figure indicate the observed lineage 
interchangeability. Adapted from (Zhou et al., 2009). 
The Th2 cells, on the other hand, which produce high levels of IL-4, IL-5 and IL-13, are 
required for development of humoral immunity controlling helminths and other extracellular 
pathogens. Differentiation of Th2 cells is directed by the transcription factors GATA binding 
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protein 3 (GATA3) and Stat6, both downstream targets of IL-4 (Ansel et al., 2006). 
Differentiation towards the more recently identified Th17 cell lineage appears to be important 
for clearance of certain extracellular bacteria and fungi, particularly at the mucosal surfaces. 
The cells of this lineage are characterized by the simultaneous production of IL-17A, IL-17F 
and IL-22 cytokines. Their differentiation is linked to the expression of the transcription 
factor retinoic acid receptor-related orphan receptor (ROR)-C, induced by tumor growth 
factor  (TGF-) in concert with the pro-inflammatory cytokines IL-6, IL-21 and IL-23, all of 
which are known to induce phosphorylation of Stat3 (Chen et al., 2007). Differentiation of 
Tfh cells, being essential regulators of B cell differentiation and memory B cell development, 
requires the cytokine IL-21 and induction of the transcription factor B cell lymphoma 6 (Bcl-
6) protein (Crotty, 2011). Further details about the possible functional fates of naive CD4+ T 
cells are indicated in Figure 4. 
1.1.5 Humoral immunity 
As described in section 1.1.3, the key feature of the adaptive immune system is the ability to 
remember experiences in the past and respond with heightened kinetics and efficacy to re-
challenges by the same pathogen. In addition to inducing activation of CD4+ T cells, as 
described earlier, infections caused by extracellular pathogens also initiate production of high-
affinity antibodies by antigen-specific B cells (Rajewsky, 1996). This is essential for clearing 
extracellular infections and constitutes the basis for humoral immunity as well as design of 
efficacious vaccines. The high serum stability of antibodies and their continuous 
replemenishment by long-lived plasma cells (PCs) ensure lasting protection (McHeyzer-
Williams and McHeyzer-Williams, 2005;Tarlinton, 2006). 
The antigen receptor expressed on the surface of naive B cells is called the B cell receptor 
(BCR) and is composed of membrane bound immunoglobulins (Igs) of the IgM and IgD 
classes (Goding et al., 1977;Meffre et al., 2000). Despite some structural differences, these 
molecules are considered to be the counterpart of the TCR in T cells. Consequently, BCRs are 
the receptors responsible for recognition of soluble antigens in the initial phase of B cell-
mediated immune responses. The BCR constitutes two identical heavy chains and two 
identical light chains linked together by disulfide bounds (Reth, 1992). The light chains, 
which are expressed as either kappa () or lambda () subunits on individual B cells, 
constitute the BCR unit responsible for antigen recognition. The heavy chains, on the other 
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hand, dictate the functional properties of the Igs. These exist in five different isotypes, 
designated by the Greek letters as , , , 	 and 
 that define the corresponding Ig classes: 
IgA, IgG, IgD, IgE and IgM, respectively. 
Characteristically, B cells release their antigen receptor into the surrounding environment in 
the form of pathogen-specific antibodies that may neutralize or, with the aid of complement 
factors or cellular mediators, kill the target pathogen. Thus, B cells are the cells responsible 
for humoral immunity. The B cells are activated as their BCR recognizes an extracellular 
pathogen. This leads to activation of intracellular signaling cascades, resulting in B cell 
proliferation and differentiation (Kurosaki et al., 2010). For details about the signaling events 
induced in response to antigen-recognition by the BCR, see section 1.2.5. 
During a primary immune response, naive B cells may choose either one of three fates upon 
activation through the BCR (Nutt and Tarlinton, 2011) (Figure 5). Most of them will follow 
the extra-follicular pathway and rapidly differentiate into short-lived plasmablasts, with a 
half-life of approximately 3-5 days, which give rise to the first transient wave of antibody 
defense against the invading pathogen (McHeyzer-Williams and McHeyzer-Williams, 
2005;Ho et al., 1986;Jacob et al., 1991). Notably, the antibodies produced in this stage are of 
low-affinity for the specific antigen. Although most of the activated B cells follow the extra-
follicular pathway, a few of them will follow the follicular one, undergoing intense 
proliferation and migrate from the outer face of the B cell follicle to the center of it where 
they start forming a specialized structure known as germinal center (GC) (Allen et al., 
2007;MacLennan, 1994) (Figure 5). Several essential molecular processes will take place 
within the GC in order to develop efficient long-lasting serological immunity. These 
processes include class-switch recombination (CSR) and somatic hypermutation (SHM) of the 
constant and variable regions of the Ig genes, respectively, in addition to clonal selection of 
high-affinity B cells (Berek et al., 1991;Jacob et al., 1991;Tarlinton and Smith, 2000;Liu et 
al., 1996). Thus, the antibodies produced by the terminally differentiated GC B cells have a 
drastically improved affinity for the activating antigen and with isotypes that are relevant for 
more efficient clearances (Niiro and Clark, 2002). Following these processes, GC B cells will 
emigrate from the follicle and differentiate into either high-affinity memory B cells or long-
lived PCs (Figure 5), both contributing to enhance protection to the host for protracted time 
(Nutt and Tarlinton, 2011). The long-lived PCs primarily migrate to and reside in the bone 
marrow, where they continuously secrete high levels of antibodies for prolonged periods of 
10 
 
time well after the primary response have subsided. The memory B cells, on the other hand, 
will remain circulating in the periphery and maintain their ability to rapidly proliferate and 
differentiate into plasmablasts following re-exposure to the same antigen (Tarlinton, 
2006;Good-Jacobson and Shlomchik, 2010). Hence, memory B cells and long-lived PCs will 
contribute to efficient elimination and reduced collateral tissue damage upon re-challenges by 
the same pathogen. This ability of naive B cells to develop into either memory B cells and 
long-lived PCs is the basis for the design of the majority of the vaccines that are currently in 
use (Plotkin, 2008). 
Although the majority of the activated B cells undergo isotype switching in the GC, some will 
undergo isotype switching without prior SHM and give rise to early memory B cells (Figure 
5). During this process, the variable portion of the Ig that binds to the antigen maintains its 
antigen specificity. Nevertheless, the humoral immune response diversifies as the distinct 
classes of Igs have different functional properties. In the first phase of the immune response 
the abundance of antigens allows for both low- and high-affinity interactions with antigen-
specific B cells, as the affinities of the antibodies produced are heterogeneous. However, as 
the response progresses and a large number of antibodies are bound to antigens, the amount of 
available antibodies gets markedly reduced. At this point, a process called affinity maturation 
starts, wherein the B cells expressing the higher affinity antibodies are preferentially 
stimulated. This process, which is dependent on help from Tfh cells localized in the T cell 
zone of secondary lymphoid organs (Crotty, 2011), increases the affinity of the secreted 
antibodies for a certain antigen, and is the result of SHM in the variable portion of the Ig gene 
during clonal expansion. Positive selection ensures that only the B cells capable of producing 
antibodies with higher affinity for the specific antigen survive. Interaction between B cell-
expressed CD40 and Tfh-expressed CD40L (Bishop and Hostager, 2001), as well as the 
presence of IL-4 and IFN secreted by activated Tfh cells, serve to facilitate CSR and 
formation of GC (King, 2009).  
The differentiation of B cells is a highly controlled process (Niiro and Clark, 2002). 
Consequently, signaling through the BCR is tightly regulated in order to prevent erroneous B 
cell development and ensuing tissue damage. In Paper III, we used an established phospho-
specific flow cytometry protocol to compare early BCR signaling in both normal and 
transformed B cells in an attempt to elucidate the role of the adaptor protein phosphoprotein 
associated with glycosphingolipid-enriched microdomains (PAG) in BCR signaling. Notably, 
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this adaptor protein has been shown to negatively regulate proximal TCR signaling in T cells. 
For further details about the function of this transmembrane adapter protein, see section 1.2.2. 
 
 
Figure 5. B cell follicles are necessary for development of humoral immunity. Shortly, the 
lymphocytes in the secondary lymphoid organs are segregated into distinct zones based on their 
sensitivity to various chemokines (Cyster, 2005). These zones are called B cell zones (follicles) and T 
cell zones that are specialized regions for B- and T cells, respectively. Initially priming of antigen-
specific T cells by DC in the T cell zone induces up-regulation of ICOS, PD-1 and the chemokine-
receptor CXCR5 on the T cells, which subsequently migrate toward the interface between the zones. In 
this interface, the T cells will interact with cognate B cells and mature into Tfh cells. The follicular B 
cells will migrate in response to antigen-induced up-regulation of the chemokine receptor CCR7 to the 
border of the T cell zone in search for T cell help. Upon interaction with cognate T cells, the activated B 
cells will differentiating into plasmablasts, giving rise to early memory B cells that have not undergone 
affinity maturation or they will return back to the center of the follicle to form specialized GC. The B 
cells of the GC interact with Tfh cells by means of multiple molecular pairings, including among others 
the interactions between the TCR and MHC, the CD28-B7 family members, ICOS and its ligand ICOSL, 
and CD40L and CD40 (see insert). These pairings induces secretion by Thf of IL-4 and IL-21, which 
dictate the B cell to differentiate into either affinity-matured memory B cells or long-lived PCs. Adapted 
from (Nutt and Tarlinton, 2011). 
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1.2 Immune cell signaling and activation 
The antigen-specific cells of the immune system, which are divided into the B- and T cells, 
are maintained in the quiescent G0 stage of the cell cycle and require potent antigen 
stimulation to progress from this phase. Of note, the antigen receptors of the B- and T cells 
recognize fundamentally distinct forms of the antigens: whereas the BCR recognizes the 
native or denatured form of proteins, or carbohydrates in soluble, particulate or cell-bound 
form, the TCR recognizes short, proteolytically processed peptide antigens (8 ~ 15 residues) 
bound to MHC molecules on the surface of an APC. Although the structures of these two 
receptors are quite different, the signal transduction events initiated by their engagement are 
remarkably similar. 
1.2.1 Signal integration by post-translational phosphorylation 
Among the various mechanisms for regulating cellular processes, post-translational 
modifications (PTMs) have a central role in creating highly dynamic and largely reversible 
relay systems that interpret and respond to alterations in the cellular microenvironments. The 
PTMs include modifications such as proteolytic cleavage or the addition of chemical groups 
or proteins to one or more amino acids of the target protein. To date, over 200 different PTMs 
have been reported (Deribe et al., 2010), contributing among others to the diversity in inter- 
and intracellular signaling and relay of fast messages throughout the cells. Whereas some 
PTMs are stable, like those involved in maturation and folding of newly synthesized proteins 
(e.g., glycosylation, lipidation and formation of disulfide bridges), others such as 
phosphorylations are more transient, but nonetheless crucial for efficient intracellular 
signaling (Deribe et al., 2010). In the present Thesis, we have studied phosphorylation-based 
signal integration in response to a variety of stimuli in functionally distinct immune cell 
populations. Thus, the following focuses on post-translational phosphorylation processes. 
Intracellular phosphorylation of serine, threonine and tyrosine residues in eukaryotic cells 
(Deribe et al., 2010;Narayanan and Jacobson, 2009) is one of the main mechanisms by which 
a cell modulate the intrinsic biological activity of proteins, as well as their turnover, 
localization and interaction with other proteins (de et al., 2006;Sefton and Shenolikar, 2001). 
Accordingly, reversible phosphorylation controls a multitude of cellular processes. In the 
initiation of diverse phosphorylation responses, extracellular stimulation of cells trigger 
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signals which are transduced, amplified and regulated by kinase cascades that are turned on 
and off by means of reversible addition (by kinases) or removal (by phosphatases) of 
phosphate groups (White, 2008;Hunter, 2000;Cohen, 2000). As such, phosphorylation and 
dephosphorylation processes are known to regulate the majority of the aspects of cell 
function, including cell growth, metabolism, apoptosis, and intercellular communication and 
coordination (White, 2008;Schlessinger, 2000). Of the entire proteome, the enzymes that 
control phosphorylation events in eukaryotic cells amount to 1.5-2.5% (Manning et al., 2002), 
indicating that post-translational phosphorylation is an important and ubiquitous regulatory 
mechanism in eukaryotic cells. Whereas cellular processes affected by phosphorylation of 
serine and threonine residues include cell-cycle progression and control of cellular growth, 
phosphorylation of tyrosine residues are initiated predominately by surface-bound receptors 
involved in the regulation of cellular proliferation and differentiation (Ullrich and 
Schlessinger, 1990;Deribe et al., 2010). 
Modulating a protein by the addition of a phosphate group gives it an extra charge of -2 at 
physiological pH, which provokes a perturbation of the tertiary structure through a 
conformational change that may either affect its enzymatic activity and/or interactions with 
other molecules (Narayanan and Jacobson, 2009;Johnson and Lewis, 2001). Thus, in addition 
to inducing changes in intrinsic activity, phosphorylation may also initiate creation of docking 
sites for interactions with other molecules. For example, phosphorylated serine residues 
appear to interact with forkhead-associated domains. Furthermore, phosphorylated tyrosine 
residues are known to interact with Src homology 2 (SH2) domains or other phosphotyrosine-
binding (PTB) domains of the interacting proteins (Deribe et al., 2010). In the case of 
interaction between pTyrosine (pY) residues and SH2 domains, the pY residue binds to a 
conserved pocket in the cassette-like structure of the SH2 domain by ionic interactions with a 
strictly conserved arginine (Johnson and Lewis, 2001;Pawson, 2004). This interaction is 
further strengthened by the ability of the SH2 domain to interact with other N- and C-terminal 
residues in juxtaposition to the pY-binding domain. 
Around 30% of all cellular proteins are estimated to be phosphorylated in vivo (Cohen, 2000). 
In this context, abnormal phosphorylation patterns have been demonstrated to be either the 
cause or result of numerous diseases, e.g., diabetes, rheumatoid arthritis and several types of 
cancer (Blume-Jensen and Hunter, 2001;Ostman et al., 2006). Drugs affecting kinases or 
phosphatases have been used to treat different diseases, and new modulators of these may 
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thus have therapeutic potential. In spite of the recent intensity with which phosphorylation 
events have been studied, extensive work remains in order to map signaling pathways 
associated with diverse biological processes and responses, and to identify the phospho-
proteins involved (Kosako and Nagano, 2011;White, 2008). 
1.2.2 PAG - a transmembrane adaptor protein 
The process of immune-cell activation relies on organized and coordinated assemblies 
throughout the cell of both kinases and phosphatases, ultimately leading to the induction of 
cellular responses, which depend on the character of the stimulus and the receptors involved. 
Critical in this context are the transmembrane adaptor proteins (TRAPs), which act as 
molecular scaffolds that do not possess enzymatic activity, but provide docking sites for 
cytosolic effector molecules (Horejsi et al., 2004). The TRAPs ensure clustering of signaling 
complexes in the proximity of the plasma membrane, and contribute to co-localization and 
integration of the signals initiated by these. This condensation of signals is crucial for the 
efficient transduction of antigen receptor-induced signaling responses. 
Currently, at least seven different TRAP members have been identified. These may be divided 
into two groups based on their ability to target specialized microdomains of the plasma 
membrane called lipid rafts. The lipid rafts serve as platforms for antigen receptor signaling in 
both B- and T cells, clustering the antigen receptors with effector molecules necessary for the 
initiation of productive signaling (Pierce, 2002;Simons and Toomre, 2000). One of these two 
TRAP groups encompasses the adaptor proteins that associate with the glycosphingolipid-
enriched microdomains (GEMs). The members of this group include linker for activation of T 
cells (LAT) (Zhang et al., 1998), phosphoprotein associated with glycosphingolipid-enriched 
microdomains (PAG; also referred to as the Csk-binding protein [Cpb]) (Brdicka et al., 
2000;Kawabuchi et al., 2000), non-T cell activation linker (NTAL; also called the linker for 
activation of B cells [LAB]) (Brdicka et al., 2002;Janssen et al., 2003), and finally the Lck-
interacting molecule (LIME) (Hur et al., 2003;Brdickova et al., 2003). The rest of the TRAP 
members belong to the group of TRAPs that are excluded from the lipid rafts, called the non-
GEM associated TRAPs; the TCR-interacting molecule (TRIM) (Bruyns et al., 1998), SHP-2-
interacting transmembrane adaptor protein (SIT) (Marie-Cardine et al., 1999) and linker for 
activation of X cells (LAX) (Zhu et al., 2002). 
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The GEM-associated TRAPs consist of a short extracellular domain, a single transmembrane 
region terminated by a CxxC palmitoylation motif, and a long cytoplasmic tail that contains a 
varying number of tyrosine based signaling motifs, which dictate their docking properties 
(Horejsi et al., 2004). The protein tyrosine kinases (PTKs) of the Src and spleen tyrosine 
kinase (SYK) families phosphorylate and regulate the binding properties of the GEM-
associated TRAPs. Thus, these adaptor proteins serve an important regulatory function 
through their interactions with PTKs, playing a crucial role in connecting signals initiated by 
cell-surface receptors with downstream signaling pathways. Our investigations into the in 
vitro regulatory function of PAG in early BCR signaling are presented in Paper III. Thus, the 
remainder of this section will described this particular TRAP member in more detail. 
The adaptor was identified simultaneously by two independent groups and was named PAG 
(Brdicka et al., 2000) or Cbp (Kawabuchi et al., 2000). The two discovering labs 
characterized PAG as a heavily phosphorylated protein with the ability to target lipid rafts and 
provide docking sites for the negative regulatory C-terminal Src kinase (Csk). As described in 
section 1.2.3, TCR-transduced signaling is initiated by the activation of the Src family of 
PTKs (SFKs) Lck and Fyn. The activities of these kinases are under negative control by Csk, 
which phosphorylates a conserved, inhibitory C-terminal tyrosine residue of Lck and Fyn, and 
thereby prevents their activation (Chow et al., 1993;Okada et al., 1991). 
Compared with the other TRAPs, PAG appears to be unique in being ubiquitously expressed 
rather than restricted to specific hematopoietic cell lineages (Brdicka et al., 2000;Kawabuchi 
et al., 2000). In spite of being expressed by several different cell types, investigations 
regarding its function have mainly been performed using T cells and T cell derived cell lines. 
In resting T cells, the Src kinase FynT (the T cell specific form of Fyn) is responsible for 
keeping PAG in a heavily tyrosine-phosphorylated state (Yasuda et al., 2002;Shima et al., 
2003). Human PAG carries ten tyrosine-based motifs where nine of these have been 
demonstrated to be susceptible for phosphorylation by PTKs (Ingley et al., 2006). In 
particular, phosphorylation of Y317 in human PAG (Y314 in murine PAG) provides a 
docking site for the SH2 domain of Csk (Brdicka et al., 2000;Kawabuchi et al., 2000). 
Association of Csk with PAG enhances the catalytic activity of this kinase, bringing it into the 
vicinity of its substrate and facilitating phosphorylation of the inhibitory tyrosine (pY505) of 
Lck (Takeuchi et al., 2000;Vang et al., 2001;Vang et al., 2003). In response to TCR 
stimulation, PAG is rapidly and transiently dephosphorylated, presumably by CD45, resulting 
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in dissociation of the PAG/Csk complex (Brdicka et al., 2000;Davidson et al., 2003;Torgersen 
et al., 2001). This is necessary in order for proper T cell activation to occur, indicating that 
Csk-mediated inhibition of Lck, being regulated by PAG, provides a negative regulatory 
feedback loop which sets the threshold for TCR activation. Accordingly, PAG, through its 
capacity to recruit Csk and inactivate the Src kinases, appear to negatively regulate T cell 
activation (Figure 6). Surprisingly, no effect was observed on embryogenesis, development of 
the thymus and the function of T cells in PAG knockout mice (Dobenecker et al., 2005;Xu et 
al., 2005), although a reduced level of raft-associated Csk was demonstrated (Xu et al., 2005). 
Taken together, these findings indicate that the development and activation of T cells is 
safeguarded by other compensatory mechanisms that have the ability to regulate the activity 
of Csk. 
As mention in the beginning of this chapter, the signaling responses initiated by engagement 
of the TCR- and BCR receptors are remarkably similar. Combined with the fact that PAG is 
ubiquitously expressed, we attempted in Paper III to investigate whether this adaptor protein 
exhibit a similar regulatory role in antigen-induced signaling in B cells as has been found in T 
cells. 
1.2.3 Overview of TCR signaling 
During an immune response, T cells become activated by antigens through the engagement of 
the TCR and the associated CD3/ complex. This eight-chain complex constitutes at least two 
functional units. The extracellular domain of the clonotypic TCR  chains is involved in 
binding of the antigen, while the  chains and the CD3 subunits (,  and 	) participate in 
signal transduction. All of the TCR/CD3 complex subunits are transmembrane proteins. The 
antigen-recognizing  and  chains each contains a single membrane-spanning region with 
very short cytoplasmic domains. The CD3/ subunits have larger cytoplasmic tails that 
participate in signal transduction. Experiments performed nearly three decades ago in an 
attempt to test the independent role of the different components of the TCR, unraveled that 
the co-expression of the CD3/ subunits with the  chains were necessary for an efficient 
expression of the receptor to occur (Weiss and Stobo, 1984). Although it was discovered quite 
early that the CD3/ subunits following TCR ligation transduce the signals, it remains 
controversial exactly how the first signal is transduced (Smith-Garvin et al., 2009). 
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Upon binding to the MHC complex, the TCR undergoes conformational changes leading to 
activation through phosphorylation of the activation site of either one or both of the SFKs Lck 
and Fyn (Straus and Weiss, 1992;Veillette et al., 1988b;Veillette et al., 1989), which 
phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) (Reth, 1989) in the 
cytoplasmic portions of the TCR-associated CD3- and  chains (Samelson et al., 1986). Lck 
and Fyn have been reported to associate with both the TCR (Samelson et al., 1990) and the 
CD4- and CD8 coreceptors (Veillette et al., 1988a;Barber et al., 1989). Nevertheless, earlier 
studies have demonstrated a more specific role for Lck than Fyn with regard to regulation of 
the tyrosine phosphorylation of the ITAMs (van Oers et al., 1996). Phosphorylated ITAMs 
contain two tyrosine residues which serve as docking sites for the tandem SH2 domains of the 
PTK -chain-associated protein of 70 kDa (ZAP70) (Chan et al., 1991;Chan et al., 
1992;Weiss and Littman, 1994), a member of the SYK family of non-receptor tyrosine 
kinases. Consequently, ZAP70 associates with the TCR only when the cell becomes activated 
following ligation of the receptor (Chan et al., 1991). Importantly, this positions ZAP70 in the 
vicinity of Lck, which activates the former through phosphorylation of key tyrosine residues 
(Chan et al., 1992) (Figure 6). Activated ZAP70 phosphorylates the transmembrane adaptor 
molecule LAT of 36-38 kDa (Zhang et al., 1998) and subsequently the cytosolic adaptor 
molecule SH2 domain-containing leukocyte-specific phosphoprotein of 76 kDa (Slp-76) 
(Bubeck et al., 1996), leading to formation of a LAT/Slp-76 nucleated signaling complex 
(Smith-Garvin et al., 2009). This complex orchestrates the activation of signaling proteins 
involved in a number of processes important for T cell activation including reorganization of 
the cytoskeleton through activation of phospholipase C1 (PLC1), which controls the 
calcium- and diacylglycerol (DAG)-mediated activation of calcineurin, nuclear factor of 
activated T cells (NFAT), protein kinase C  (PKC) and Ras guanyl nucleotide-releasing 
protein (RasGRP) (Figure 6). RasGRP is a positive regulator of Ras and hence the Ras-Raf-
Mek-Erk signaling pathway, leading to activation of the transcription factor activator protein 
1 (AP1) (Smith-Garvin et al., 2009). PKC, on the other hand, is implicated in signaling 
events eventually activating the transcription factor, nuclear factor B (NF-B), which is a 
key regulator of immunological reactions. However, in contrast to NFAT and AP1, NF-B 
activation is very weak when only the TCR is triggered (Kane et al., 2001). 
A central theory in T cell activation is that induction of the TCR in the absence of proper co-
ligation of other cell surface receptors keeps the T cells in a non-responsive state called 
anergy, in which the cells become refractory to restimulation rather than get activated and 
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proliferate (Appleman and Boussiotis, 2003). For this reason, it is accepted in the field that 
additional signals to TCR-induced signaling is necessary in order to ensure productive T cell 
activation instead of inducing anergy (Smith-Garvin et al., 2009). Costimulation is discussed 
in the next section. 
 
Figure 6. Overview of some of the signaling pathways involved in T cell activation. See the text 
for further details. This grafic illustration combines information from numerous publications from the T 
cell signaling field. 
1.2.4 Coreceptors for signal transduction initiated by the TCR 
Based on the fact that TCR signaling alone is not sufficient to induce activation of NF-B, 
concurrent costimulatory signals have been suggested to play a key role in the ultimate 
activation of this transcription factor. The role of costimulatory molecules is at least two-fold, 
involving both reduction of the threshold for TCR signaling and contribution of additional 
signals necessary for optimal T cell activation, pushing the cells from a resting state to 
commit to proliferation and subsequent differentiation (Iezzi et al., 1998). The underlying 
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molecular mechanisms for the effects of costimulation remain in part elusive, but most 
probably involve augmentation of signaling pathways that also are activated by TCR 
stimulation alone (Acuto and Michel, 2003). For instance, costimulation with CD28 will both 
lower the threshold for TCR signaling and induce robust activation of NF-B (Kane et al., 
2001;Kane et al., 2002;Schulze-Luehrmann and Ghosh, 2006). Two signaling pathways have 
been implicated to explain the link between CD28 and NF-B, and there may even be 
crosstalk between these. The first pathway involves growth-factor receptor-bound protein 2 
(Grb2)/Vav-mediated activation of PLC1/PKC (Marinari et al., 2002;Zhang et al., 
1995;Tarakhovsky et al., 1995), while the second encompasses activation of 
phosphatidylinositol 3-kinase (PI3K) (Figure 6). As CD28 lack enzymatic activity, it mediates 
signaling through the binding of SH2 and SH3 domains of intracellular signaling proteins to 
corresponding tyrosine and proline-based motifs of its cytoplasmic tail (Ward, 1996). 
Phosphorylation by either Lck or Fyn of one well-studied motif of CD28, the YMNM 
sequence (Prasad et al., 1994;Hutchcroft and Bierer, 1994), leads to binding of the SH2 
domain of PI3K (August and Dupont, 1994;Pages et al., 1994;Prasad et al., 1994;Stein et al., 
1994;Truitt et al., 1994) and the adaptor protein Grb2 (Raab et al., 1995;Schneider et al., 
1995). Grb2 also bind via its two SH3 domains to the C-terminal diproline motif of CD28 
(Kim et al., 1998;Okkenhaug and Rottapel, 1998). Activation of PI3K initates 
phosphorylation of phosphatidylinositol with the resulting production of phosphatidylinositol-
(3,4)-biphosphate (PIP2) and phosphatidylinositol-(3,4,5)-triphosphate (PIP3) (Okkenhaug and 
Vanhaesebroeck, 2003;Rudd et al., 2009). These lipids, known as D-3 lipids, will associate 
with the plasma membrane and subsequently recruit other signaling proteins such as 
phosphoinositide-dependent protein kinase 1 (PDK1) through the binding of their pleckstrin 
homology (PH) domains (Okkenhaug and Vanhaesebroeck, 2003). Activation of PDK1 
facilitates activation of protein kinase B (PKB/Akt), which in turn induces auto-
phosphorylation, activation and regulation of other downstream signaling events (Riha and 
Rudd, 2010;Rudd et al., 2009). Recruitment of Grb2 to the YMNM motif of CD28 initates 
signaling through activation by phosphorylation of Vav1 or the binding of the exchange factor 
Son of Sevenless (SOS) (Riha and Rudd, 2010). SOS is an activator of the Ras GTPase 
(Boriack-Sjodin et al., 1998) and consequently induces activation of the MAPK/Erk pathway 
(Figure 6). Cooperation of Grb2 with Vav1 leads to activation of Rac1, which in turn 
activates c-Jun N-terminal kinase (JNK) (Kim et al., 1998) that is necessary for translocation 
of PKC to the site of activation (Riha and Rudd, 2010). Studies have shown that Vav1 and 
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Rac1 coordinately facilitate micro-clustering of kinases and adaptor proteins into 
immunological synapses that are necessary in order to ensure optimal T cell activation 
(Monks et al., 1998;Grakoui et al., 1999). 
The importance of the costimulatory contribution of CD28 has been tested in CD28-deficient 
mice, where a reduced proliferation of T cells in response to antigenic stimulation has been 
observed (Green et al., 1994;Shahinian et al., 1993). However, repeated antigen stimulation or 
long-term viral infections have shown to overcome CD28 deficiency. Interestingly, the 
relatively mild phenotype associated with CD28 deficiency suggests that other costimulatory 
molecules can compensate for the loss of CD28, and CD2 has been proposed to play such a 
role (Green et al., 2000;Sasada and Reinherz, 2001;Shahinian et al., 1993). CD2 has been 
demonstrated to act both as an adhesion molecule as well as a signaling molecule (Bachmann 
et al., 1999;Bierer et al., 1988;He et al., 1988;Kanner et al., 1992;Moingeon et al., 1989), 
although its role in T cell activation is not clearly defined. Results from previous studies 
indicate that CD2 cross-linking can induce proliferation of T cells and secretion of cytokines, 
both events mediated through the activation of ZAP70 (Martelli et al., 2000;Meinl et al., 
2000). Independent of TCR stimulation, interactions between CD2 and its ligand CD58 
appear to induce signaling through formation of CD2 clusters in distinct membrane 
microdomains (Kaizuka et al., 2009). Additionally, transgenic expression of CD2 in 
developing thymocytes results in increased apoptosis at the double positive stage, suggesting 
that CD2 generates signals that resemble the ones derived from the TCR (Melton et al., 1996). 
Along these lines, both Lck and Fyn have been shown to interact with CD2 and to become 
activated in response to CD2 cross-linking (Bell et al., 1996;Carmo et al., 1993;Danielian et 
al., 1992;Lin et al., 1998). Interestingly, the ITAM domains of the TCR-associated CD3- and 
 chains appear to be required for propagation of CD2-mediated signals (Bockenstedt et al., 
1988;Moingeon et al., 1992;Alcover et al., 1988). Additionally to be important for the 
formation of IS (Kaizuka et al., 2009), some studies indicate that activation through CD2 
induces exclusion of CD45 and enrichment of PKC in the interface between the T cells and 
their cognate APCs (Dustin et al., 1998;Bagnasco et al., 1989;Zaru et al., 2002). Notably, the 
identification of the function of this coreceptor has been complicated by the fact that CD2 
knockout mice only show partial defects in immune responses (Killeen et al., 1992). Thus, 
similar to CD28-deficient T cells, CD2-deficient T cells are only mildly affected, indicating 
some redundancy. However, the combined lack of CD28 and CD2 led to profound defects in 
activation and proliferation of T cells (Green et al., 2000), suggesting the necessity of at least 
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one of these two costimulatory molecules for induction of proper T cell function. In Paper II, 
we investigated the relative contribution of CD2 and/or CD28 in induced activation or 
inactivation by means of phosphorylation of known signaling molecules downstream of the 
TCR. 
1.2.5 BCR-induced signaling responses 
Similar to the TCRs, the BCRs are composed of two functional units. As described in section 
1.1.5, the membrane bound Ig constitutes the antigen-binding subunit of the BCR, ensuring 
antigen recognition. The other functional unit of the antigen receptor is composed of a non-
covalently disulphide-linked Ig/Ig heterodimer, which is responsible for initiating 
intracellular signaling upon antigen binding (Figure 7). Comparable to activation of the TCR, 
ligation of the BCR initially leads to phosphorylation of the Ig/Ig ITAMs with resulting 
conformational opening of their cytoplasmic domains (Reth and Wienands, 1997;Tolar et al., 
2005). In contrast to TCR-induced signaling, this initial phosphorylation process is mediated 
preferentially by the SFKs Lyn rather than Lck (Dal Porto et al., 2004;Sohn et al., 2006). B 
cells do also express other SFKs, specifically Fyn, Blk, Fgr and Hck, but in contrast to Lyn, 
mutations of these have demonstrated minor effect on B cell development and activation 
(Lowell and Soriano, 1996;Texido et al., 2000). 
The phosphorylated ITAMs in the open conformation serve as docking sites for the SH2 
domain-containing molecule SYK, which sequentially leads to enhanced catalytic activity of 
the kinase (Rowley et al., 1995). Particularly, activation of SYK has been demonstrated to be 
one of the key mediators in antigen-induced B cell activation, as disruption of SYK inhibits 
activation of more distal effector molecules (Jiang et al., 1998;Takata et al., 1994) as well as 
markedly blocks B cell development (Turner et al., 1995). Notably, in BCR signaling, SYK 
acts as the counterpart of ZAP70 in T cell activation. Whereas ZAP70 is exclusively 
expressed in T and NK cells (Chan et al., 1992), SYK appears to be the SYK family of PTKs 
that is preferentially expressed in B cells, myeloid cells and thymocytes (Taniguchi et al., 
1991). The recruitment of SYK to the BCR complex leads to phosphorylation of the cytosolic 
adaptor protein B cell linker (BLNK), also known as SLP65 or BASH, which is the functional 
counterpart of the combined complex of LAT and SLP76 in T cell activation (Fu et al., 
1998;Wienands et al., 1998;Goitsuka et al., 1998;Kurosaki and Tsukada, 2000). Employment 
of BLNK to the BCR complex leads to SYK-dependent activation of the TEC-family of PTK 
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Bruton’s tyrosine kinase (Btk) (Kurosaki and Kurosaki, 1997;Baba et al., 2001). Clustering of 
Btk, SYK and BLNK results in a nucleated signaling complex that orchestrates binding and 
activation of key effector molecules such as Vav, Grb2 and PLC2 (Fu and Chan, 1997;Fu et 
al., 1998;Hashimoto et al., 1999;Ishiai et al., 1999;Wienands et al., 1998;Chiu et al., 2002). 
PLC2 in B cells corresponds to PLC1 in T cells (Kurosaki and Tsukada, 2000). Hence 
induced PLC2 increases the production of inositol-(1,4,5)-triphosphate (IP3) and DAG. IP3 
activation causes a surge in intracellular Ca2+ levels (Scharenberg et al., 2007) that result in 
differential activation of at least two divergent signaling pathways: calmodulin-calcineurin-
NFAT and PKC-NF-B (Dolmetsch et al., 1997;Petro and Khan, 2001;Saijo et al., 2002;Su 
et al., 2002). Production of DAG leads to recruitment of PKC and RasGRP3, where the 
former phosphorylate the latter in order to ensure full activation of RasGRP3. Immediately 
after activation, GTP-bound Ras directly bind Raf1, initiating the Mek-Erk signaling pathway 
that activates AP1 (Dal Porto et al., 2004;Hashimoto et al., 1998) in a similar manner as 
induced upon TCR stimulation. 
Although the BCR complexes are the primary signal transducers in B cell activation, receptor-
associated adaptors and coreceptors may significantly influence BCR-induced signaling both 
qualitatively and quantitatively. One important coreceptor in this respect is the 
transmembrane protein CD19, a crucial contributor in B cell activation (Dal Porto et al., 
2004;Carter and Fearon, 1992). Ligation of CD19 leads to enhanced activation of B cells 
much in the same way as CD28 influences T cell activation (Buhl et al., 1997;Carter and 
Fearon, 1992;Otero et al., 2001;Tuveson et al., 1993). Upon ligation of the BCR, Lyn rapidly 
phosphorylates multiple tyrosine residues of the cytoplasmic domain of CD19 (Fujimoto et 
al., 2000). This brings about the recruitment of SH2-domain-containing molecules such as the 
p85 subunit of PI3K, Lyn, Btk and Vav (Fujimoto et al., 2000;Tuveson et al., 1993;Weng et 
al., 1994;Buhl and Cambier, 1999;Wang et al., 2002). As in T cells, induction of PI3K leads 
to activation of PKB/Akt (Figure 7), which further inhibits the glycogen synthase kinase 3 
(GSK3) by means of phosphorylation (Gold et al., 2000). Notably, the induction of the PI3K-
PKB/Akt initiates numerous signaling cascades that ultimately activate the transcription 
factors NFAT and NF-B, both essential for proper B cell activation (Beitz et al., 1999;Gold 
et al., 2000). In the same way as for T cell, NF-B is important for both B cell development 
and proliferation (Schulze-Luehrmann and Ghosh, 2006). Although activation of PI3K is 
mainly mediated through CD19, modest PI3K activity is observed in CD19 deficient B cells 
following BCR ligation (Buhl and Cambier, 1999). This may partly be explained by the weak 
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ability of SYK to activate PI3K upon BCR-engagement. In addition to activation of the PI3K-
Akt-GSK3 pathway, associated linking of CD19 to ligation of the BCR contributes to 
enhancement of the intracellular calcium flux and activation of the Erk, JNK and p38 MAPK 
pathways (O'Rourke et al., 1998;Li and Carter, 2000). 
 
Figure 7. Overview of signaling pathways induced following ligation of the BCR. See the text for 
further details. Adapted from (Niiro and Clark, 2002;Scharenberg et al., 2007). 
The transmembrane immunoglobulin-like lectin CD22 is another crucial coreceptor in B cell 
activation. In contrast to CD19, which facilitates B cell activation, CD22 has the ability to 
modulate B cell activation negatively as well as positively (Nitschke, 2005;Sato et al., 1996). 
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Activation of CD22 induces the phosphorylation of one or more of its cytoplasmic ITAMs, 
thereby promoting the binding of the adaptor protein Grb2. The SH2 domain-containing 
tyrosine phosphatase 1 (SHP1) is also recruited to the cytoplasmic domain of the rapidly 
phosphorylated CD22 (Blasioli et al., 1999;Doody et al., 1995). However, in contrast to Grb2, 
SHP1 is recruited to two of the inhibitory tyrosine residues of CD22 collectively known as 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs), rather than to its ITAMs (Blasioli 
et al., 1999;Otipoby et al., 2001). Thus, docking of SHP1 to CD22 inhibits rather than 
promotes BCR signaling (Figure 7), thereby providing a negative feedback loop which 
contribute to tightly regulation of the BCR response (Nitschke, 2005). 
As outlined in section 1.2.2, PAG may be yet another modulator of BCR-induced signaling. It 
should be noted that the final outcome of BCR activation depends on the concomitant 
activation and recruitment of several coreceptors and adaptor molecules (some of which may 
still be unknown), and that any observed regulatory effect therefore should be interpreted with 
caution. See the discussion of Paper III (chapter 4.3) for more details about the regulatory role 
of PAG in B cell activation. 
1.3 Immune regulation by regulatory T cells 
Regulatory networks are required throughout the body to maintain homeostasis in the tissues 
and ensure the integrity of the host. The immune system also contains a small fraction of cells 
which are capable of regulating other immune cells, thereby limiting tissue damage and 
autoimmunity. The most studied of these cells are the so called CD4+CD25+ regulatory T cells 
(Tregs) (Sakaguchi et al., 1995), which have the ability to suppress both activation, 
proliferation and function of other immune cells such as CD4+ and CD8+ T cells, NK T cells, 
NK cells, B cells, macrophages and DCs (Shevach, 2009). The function of Tregs has been 
demonstrated to be important for both maintenance of immune tolerance and prevention of 
autoimmune and inflammatory diseases (Sakaguchi et al., 2008;Horwitz, 2008;Viglietta et al., 
2004;Ehrenstein et al., 2004;Lindley et al., 2005). Furthermore, Tregs appear to be key 
regulators of immune responses to infections of viral, bacterial or parasitic origin, in addition 
to possess the ability to restrain immunity directed towards both tumors and transplanted 
tissues (Belkaid, 2007;Nishikawa and Sakaguchi, 2010). The most characteristic feature of 
Tregs is their high expression of the transcription factor forkhead box P3 (FOXP3), known to 
confer to Tregs regulatory capacity by starting a Treg specific transcriptional program 
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(Fontenot et al., 2003;Hori et al., 2003;Khattri et al., 2003;Sakaguchi et al., 2010). The role of 
FOXP3 in Tregs is described in more detail in the following section. 
1.3.1 FOXP3 – an essential regulator of regulatory T cells 
The importance of Tregs has become clear through the appreciation that their dysfunction, 
due to e.g. mutations in the FOXP3 gene, leads to fatal autoimmune diseases, 
immunopathology and allergy (Zhu et al., 2010), while adoptive transfer of Foxp3-expressing 
CD4+ T cells inhibited development of autoimmunity (Tang et al., 2004;Mottet et al., 2003) 
and prevented graft rejection following organ transplantation (Waldmann et al., 2006). 
In 2003, two years after several groups had characterized Tregs as CD4+CD25+ T cells 
(Dieckmann et al., 2001;Baecher-Allan et al., 2001;Levings et al., 2001;Ng et al., 
2001;Jonuleit et al., 2001), Foxp3 was described as the master control gene for both the 
development and function of Tregs in mice (Fontenot et al., 2003;Hori et al., 2003;Khattri et 
al., 2003). The key role of the Foxp3 gene was first shown in the mouse strain Scurfy, which 
has a defective, X-linked mutant of the Foxp3 gene (Brunkow et al., 2001). This mutant had 
earlier been found to be lethal in hemizygous males within 3-4 weeks of age (Godfrey et al., 
1991), exhibiting elevated production of pro-inflammatory cytokines (Kanangat et al., 1996) 
and extensive activation of CD4+ T cells (Blair et al., 1994;Clark et al., 1999). These 
consequences were characterized by scaliness of the skin and lymphatic infiltrates in multiple 
organs, hence the name Scurfy (Godfrey et al., 1991). A few years after the identification of 
Foxp3 (scurfin) as a determining factor in murine Tregs, the human homolog, FOXP3, was 
found (Roncador et al., 2005). As with Scurfy mice containing a dysfunctional Foxp3 gene, 
mutations of the FOXP3 gene in humans has been linked to a severe autoimmune disease 
known as IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome) (Bennett et al., 2001;Wildin et al., 2001). The regulatory role of FOXP3 in Treg 
function was further emphasized by the finding that ectopic expression of Foxp3 conferred 
suppressive properties to non-regulatory peripheral CD4+CD25- T cells in mice (Hori et al., 
2003;Khattri et al., 2003;Fontenot et al., 2003), with induced expression of various cell 
surface molecules such as CD25, cytotoxic T lymphocyte antigen 4 (CTLA-4) and 
glucocorticoid-induced tumor necrosis factor (TNF)-receptor-related (GITR) protein – all of 
which are characteristically expressed at high levels in Tregs (Sakaguchi et al., 
1995;Takahashi et al., 2000;Shimizu et al., 2002;McHugh et al., 2002). 
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In spite of the fundamental role of FOXP3 in immune homeostasis, some discrepancies have 
been identified between human and mouse Tregs regarding FOXP3 expression. In mice 
Foxp3 seems to be a robust marker for both induced and thymus-derived Tregs (Hori et al., 
2003;Khattri et al., 2003;Fontenot et al., 2003). In humans, however, the expression of 
FOXP3 may become up-regulated not only in Tregs but also in non-regulatory effector T 
cells. Hence, when effector T cells are activated through the TCR, the expression of FOXP3 
increases, though generally at lower and more transient levels than in Tregs (Gavin et al., 
2006;Yagi et al., 2004). These data indicate that elevated levels of FOXP3 in humans could 
reflect an immune activation rather than the induction of regulatory mechanisms. Moreover, 
functional studies of FOXP3 have revealed that transient expression of the protein is 
insufficient to confer regulatory properties to human CD4+ T cells (Allan et al., 2005;Allan et 
al., 2007;Gavin et al., 2006;Morgan et al., 2005;Tran et al., 2007;Wang et al., 2007a). In 
contrast, a high and constitutive expression of FOXP3, independent of TCR stimulation, has 
been demonstrated to give rise to CD4+ T cells exhibiting potent suppressive activity (Allan et 
al., 2008). It has been reported that effector T cells in patients with IPEX show an impaired 
capacity of cytokine production, which is not the case in Scurfy mice (Bacchetta et al., 2006). 
Overall, these findings suggest a more intricate relationship between FOXP3 and the 
regulatory capacity of Tregs in humans than in mice, and also that additional factors may be 
required for Tregs to acquire full suppressive capacity. Furthermore, the influence of FOXP3 
in human cells may exceed its role in the development and function of Tregs, for example by 
contributing to enhanced cytokine production in effector T cells, as supported by the 
observation that CD4+ effector T cells with cytokine-producing capability express low levels 
of FOXP3 (Miyara et al., 2009). Finally, studies performed recently demonstrate that the main 
function of FOXP3 may be to stabilize the Treg function once the fate of the Tregs are 
determined, rather than controlling the development and function of these cells (Gavin et al., 
2007). 
1.3.2 Regulatory T cell subsets and modes of action 
A growing body of evidence indicates that Tregs, rather than being one distinct T cell lineage, 
comprise a number of different cell populations that collaboratively enforce immune 
homeostasis. Briefly, the Tregs have been categorized as either naturally occurring Tregs 
(nTregs), which are derived from the thymus and express FOXP3 (Sakaguchi et al., 
1995;Sakaguchi et al., 2001;Shevach et al., 2001;Shevach, 2002), or inducible Tregs (iTregs), 
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which are induced in secondary lymphoid organs or peripheral tissues in response to 
inflammatory stimuli (Apostolou and von, 2004;Curotto de Lafaille and Lafaille, 
2009;Knoechel et al., 2005;Kretschmer et al., 2005). Thus, the main distinction between 
iTregs and nTregs is that nTregs originate in the thymus as a distinct T cell lineage with 
specialized suppressive properties (Itoh et al., 1999;Sakaguchi et al., 1982), whereas iTregs 
acquire their regulatory capacity in the periphery when stimulated by specific antigens under 
certain conditions defined by the presence of particular sets of cytokines (Curotto de Lafaille 
and Lafaille, 2009;Josefowicz and Rudensky, 2009;Sakaguchi et al., 2008). As a result, iTregs 
are generated by some of the same processes that lead to the development of effector T cells 
and may therefore represent a natural consequence of protective immunity. Accordingly, the 
TCR repertoire of iTregs are similar to, whereas those of nTregs significantly differ from, the 
TCR repertoire of conventional T cells (Hsieh et al., 2006;Pacholczyk et al., 2006;Scheinberg 
et al., 2007;Wong et al., 2007). Importantly, the broad TCR repertoire of nTregs, with 
specificities that matches both naive and autoreactive T cells, may enable them to control 
immunological as well as immunopathological reactions. 
Although nTregs and iTregs are difficult to discriminate phenotypically, even with respect to 
their expression of FOXP3, they may differ in function and stability (Curotto de Lafaille and 
Lafaille, 2009). It has been shown that iTregs contribute minimally to the pool of Tregs in 
homeostatic conditions and that they are more likely to hold back an escalating immune 
response than to prevent it in the first place. Importantly, it has been hypothesized that the 
main function of nTregs is to protect against autoimmune responses in the periphery by 
neutralizing self-reactive T cells that have escaped negative selection in the thymus. However, 
recent studies indicate that nTregs are preferentially recruited and expanded in infectious 
settings instead of the conversion of conventional T cells to iTregs (Feuerer et al., 2009). 
Along this line, iTregs appear to act locally and preferentially at mucosal tissues, such as the 
intestines and the lungs, and in the skin (Campbell and Koch, 2011). In these tissues, they are 
destined to modulate an ongoing immune response in order to prevent the infected tissues 
from being needlessly damaged once an infection has been cleared. 
The activity of Tregs depends on several factors: the cytokine environment, the strength and 
duration of TCR stimulation, and the nature and extent of costimulatory signals. A number of 
mechanisms for Treg-mediated suppression have been proposed (Figure 8), including the 
secretion of immunosuppressive cytokines, killing through cytolysis, disruption of the 
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metabolic function of target cells, and inhibition of DC maturation and/or functional 
modification of DCs (Campbell and Koch, 2011;Shevach, 2009;Vignali et al., 2008). Notably, 
a recent study in mice (Wing et al., 2008) has demonstrated that one of these mechanisms, 
mediated by CTLA-4 which is constitutively expressed by Tregs (Read et al., 2000;Takahashi 
et al., 2000), is crucial for their suppressive function both in vitro and in vivo. It is not yet 
clear whether one or several of the proposed mechanisms need to be activated at the same 
time in order to ensure maximal suppressive function (Vignali et al., 2008). However, both 
the site of action and the inflammatory environment are likely to influence the mechanism(s) 
of suppression exerted by the Tregs (Campbell and Koch, 2011). 
As indicated in section 1.3.1, FOXP3 may be expressed by suppressive as well as non-
suppressive T cells in humans, suggesting that FOXP3+ T cells are functionally heterogeneous 
and consequently that FOXP3 does not equivocally identify human Tregs. A recent 
publication by Miyara et al. suggested that CD4+ T cells in human blood may be divided into 
five different categories based on their combined expression of CD45RA/RO, CD25 and 
FOXP3 (Miyara et al., 2009) (Table 1). 
Table 1. Phenotypes of defined subsets of CD4+ T cells. 
Cell subset Phenotypic features 
conventional naive T cells CD45RA+/CD45RO-CD25-FOXP3- 
conventional effector/memory T cells CD45RO+/CD45RA-CD25-FOXP3- 
cytokine-producing effector T cells CD45RO+/CD45RA-CD25+FOXP3+ 
resting regulatory T cells (rTregs) CD45RA+/CD45RO-CD25+FOXP3+ 
activated regulatory T cells (actTregs) CD45RO+/CD45RA-CD25++FOXP3++ 
 
Two of these populations constitute the nTregs compartment, specifically the resting Tregs 
(rTregs) and activated Tregs (actTregs). While the rTregs were considered “naive” Tregs 
expressing CD45RA, the actTregs appeared to have an effector/memory phenotype as they 
expressed CD45RO (Miyara et al., 2009) (Table 1). This is in accordance with earlier 
observations published by other groups (Fritzsching et al., 2006;Seddiki et al., 2006;Valmori 
et al., 2005). Hence, the "naive" rTregs may be considered functional precursors of actTregs 
(Fritzsching et al., 2006;Ito et al., 2008;Miyara et al., 2009). The observation that rTregs in 
response to activation can proliferate and differentiate into Ki-67+FOXP3++CD45RO+ cells 
with suppressive capacities comparable to actTregs supports this notion (Miyara et al., 2009). 
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 Figure 8. Overview of currently proposed suppressive mechanisms exerted by Tregs. The 
potential mechanisms for suppression exerted by Tregs can functionally be divided into four basic 
groups of action. (A) Secretion of inhibitory cytokines, such as the immunosuppressive cytokines IL-10, 
IL-35 and TGF-. (B) Directly killing target cells by means of secreted serine proteases (granzyme A 
and B) together with perforin, leading to cytolysis.  (C) Disruption of the metabolic activity of target 
cells, including induced apoptosis through CD25-dependent deprivation of IL-2 in the 
microenvironment; cyclic adenosine 3’, 5’ monophosphate (cAMP)-mediated inhibition by means of 
gap-junctions; adenosine receptor 2A (A2AR)-mediated immune suppression generated by CD35- and/or 
CD73; and COX-2–PGE2–EP2/4-mediated T cell inhibition as observed in iTregs  (see section 1.4.3.). (D) 
Functional modification or inhibition of maturation of the DCs required for activation of effector T cells. 
Suggested mechanisms include pairing of lymphocyte-activation gene 3 (LAG3) on Tregs with MHCII 
on the surface of the DCs; or interaction between CTLA-4 and CD80/86 on Tregs and DCs, respectively, 
leading to induced secretion by DCs of indoleamine 2,3-dioxygenase (IDO), a potent regulatory 
molecule that is known to exert immunosuppressive mechanisms. Adapted from (Vignali et al., 
2008;Yaqub and Tasken, 2008). 
However, rTregs in the periphery are not expected to be true naive T cells (i.e. cells that have 
not yet experienced maturation by TCR-stimulation) as Tregs require continuous stimulation 
through the TCR in order to preserve (Fisson et al., 2003;Darrasse-Jeze et al., 2009). 
Interestingly, it has been known for decades that a small proportion of activated CD4+ T cells 
indeed express CD45RA and not CD45RO (Brod et al., 1989). Recently, a proportion of the 
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FOXP3+ population of CD4+ T cells was shown to constitute a non-suppressive 
subpopulation, CD4+CD45RA-FOXP3+ T cells, which had the ability to secrete high levels of 
pro-inflammatory cytokines such as IL-2, IFN- and IL-17. This subset comprises cells with a 
Th17 lineage potential (Miyara et al., 2009). 
Based on the fact that all the CD4+FOXP3+ T cells combined constitute less than 10% of all 
CD4+ T cells in the peripheral blood (Miyara and Sakaguchi, 2011), traditional biochemical 
analysis of the signal transduction in these cells has been challenging. However, the recent 
design of a technique combining FCB (Krutzik and Nolan, 2006) with phospho-flow 
cytometry enabled us to increase the resolution to a level where signaling may be studied in 
small subsets of cells and linked to their functional properties (Kalland et al., 2011;Krutzik 
and Nolan, 2003;Krutzik et al., 2004). Understanding the mechanism of Treg-mediated 
suppression is a key issue of current immunological research. The recent findings that 
FOXP3+CD4+ T cells constitute a heterogeneous population of both regulatory and non-
regulatory subsets of T cells highlight the necessity of being able to distinguish between the 
different subsets while analyzing their behavior, instead of examining the whole population as 
a uniform entity. In Paper II, we attempted to characterize the various T cell subsets on a "per 
cell" basis, studying the signaling pathways that were activated following stimulation through 
the TCR under a set of different conditions. 
1.3.3 Antigen-induced TCR signaling in Tregs 
Previous studies have demonstrated that human Tregs need to receive activation signals 
through the TCR in order to become functionally suppressive (Dieckmann et al., 
2001;Levings et al., 2001). The antigen concentration necessary to activate Tregs has been 
estimated at 10- to 100-fold below the levels required to activate naive T cells with the same 
antigen specificity (Takahashi et al., 1998). However, once activated by one particular 
antigen, the Tregs are capable of suppressing other cells irrespective of antigen specificity. 
Importantly, the suppressive potency of Tregs depends on the strength and the quality of the 
stimulus provided (Shevach, 2009). In the presence of strong costimulatory signals and/or a 
powerful TCR signal, effector T cells may acquire resistance to the suppression mediated by 
Tregs, or this may even compromise the suppressive competence of the Tregs (Baecher-Allan 
et al., 2001;Sakaguchi et al., 2010). Thus, human Tregs are not able to suppress proliferation 
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of effector T cells under conditions where the immune cells are strongly activated, which is 
the case at the beginning of an infection. 
Tregs have been demonstrated to display TCR responses that are different from those 
regularly observed in conventional naive and effector/memory T cells (see section 1.2.3). 
Although nTregs recognize antigens by means of the  TCR and show a similar repertoire in 
size compared to conventional T cells, the composition and characteristic of their TCR 
repertoire largely differ from that seen for conventional T cells (Hsieh et al., 2006;Pacholczyk 
et al., 2006;Wong et al., 2007). Whereas the engagement of the TCR induces activation and 
proliferation of conventional T cells, several human and murine studies have demonstrated 
that isolated Tregs fail to proliferate in response to stimulation through the TCR (Baecher-
Allan et al., 2001;Itoh et al., 1999;Li et al., 2005); neither do they produce pro-inflammatory 
cytokines such as IL-2, IL-4 and IFN- (Allan et al., 2005;Jonuleit et al., 2001). Regardless of 
these observations, they can not be totally unresponsive to the TCR stimulation as this is 
required for the Tregs to acquire suppressive competence (Dieckmann et al., 2001;Levings et 
al., 2001). This implies that TCR stimulation in Tregs induces intracellular signaling 
pathways other than those known to be activated in conventional T cells, resulting in the 
induction of suppressor function rather than proliferation and differentiation. Indeed, murine 
Tregs demonstrate both reduced PLC1 activation and defective calcium mobilization in 
response to TCR stimulation (Carson and Ziegler, 2007;Gavin et al., 2002). Furthermore, a 
comprehensive study in mice demonstrated that the lack of IL-2 production by Tregs was due 
to failure in the activation of the PKC and Ras/Erk pathways in response to TCR stimulation 
(Hickman et al., 2006). Supporting these data, a previous report using freshly isolated, 
primary human T cells show reduced phosphorylation of the CD3/ chains, associated with 
poor recruitment of ZAP70 and lower phosphorylation of SLP76, indicating reduction of 
proximal signaling events in these cells following TCR stimulation (Tsang et al., 2006). As in 
the previously mentioned murine studies, the reduced proximal signaling after TCR 
stimulation led to defective activation of downstream signaling events, such as the elevation 
of intracellular calcium and the activation of Erk. In contrast to anergic cells, Tregs were 
unable to regain effector function upon adoptive transfer (Knoechel et al., 2006), indicating 
that Tregs do not belong to the anergic cell population, but rather demonstrate an altered 
proximal TCR signaling that could be critical for the induction of their suppressive function.  
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Given the therapeutic potential of targeting Tregs to treat autoimmunity, allergy, chronic 
infections and some types of cancer, the molecular mechanisms governing the function of 
these cells are of great interest. In Paper II, we aimed to define the molecular signaling 
pathways initiated in different Tregs subsets upon activation and study the functional 
implications of discernible differences in signaling between these subsets. 
1.4 PGE2 in immune regulation and tumor 
biology 
Prostaglandins (PGs) are short-lived lipid mediators that are synthesized by most of the cells 
in the body in order to mediate diverse paracrine and/or autocrine effects. The E2 type 
prostaglandin (PGE2) is the one most abundantly produced in humans. The synthesis of PGE2 
is performed by various cell types and regulated by a variety of physiological and 
pathological processes, leading to a wide spectrum of biological outcomes (Matsuoka and 
Narumiya, 2007;Kobayashi and Narumiya, 2002). The role of PGE2 in immune regulation is 
discussed in more detail below. 
1.4.1 Synthesis of prostaglandins 
Prostaglandin synthesis is initiated by activation of the enzyme phospholipase A2, which 
produces arachidonic acid  (AA) and other polyunsaturated fatty acids by hydrolysis of 
phospholipids located in the plasma membrane (Funk, 2001). The resulting AA is sequentially 
converted by the enzyme cyclooxygenase (COX) to the unstable endoperoxide intermediate 
PGG2 and, subsequently, PGH2 through two distinct enzymatic processes. A variety of cell- 
and tissue-specific prostaglandin synthases (PGS) transform PGH2 into PGD2, PGE2, PGF2, 
PGI2 or thromboxane A2, all of which have a broad range of biological functions (Dey et al., 
2006) (Figure 9). 
The rate-limiting step in the prostaglandin biosynthesis is the conversion of AA to PGH2 
performed by the COX enzymes (Smith and DeWitt, 1996). To date, three different isoforms 
of COX have been indentified: COX-1, -2 and -3 (Legler et al., 2010;Park et al., 
2006;Simmons et al., 2004;Smith et al., 2000). COX-1 is constitutively expressed in most 
tissues of the body, being responsible for the basal production of PGs and accordingly crucial 
to the maintenance of homeostatic PG-dependent processes. 
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 Figure 9.  The biosynthesis of PGs. The common biosynthetic pathway of PGs is initiated by the 
activation of PLA2 leading to liberation of AA from the plasma membrane into the cytoplasm. The next 
step in this biosynthesis, specifically the conversion of AA to PGH2, constitutes the rate-limiting step in 
PG production. Depicted in this illustration are the various PGs produced, their respective receptors and 
related physiological phenomena. Emphasized in this figure is the initial events induced by PGE2. PGE2 
exerts its large number of biological functions through binding to four different subtypes of EP receptors, 
EP1-4. These receptors are rhodopsine-type receptors with seven transmembrane domains. The different 
subtypes are known to utilize distinct sets of G proteins in order to initiate different signaling pathways, 
as illustrated in the figure. Adapted from (Dey et al., 2006;Legler et al., 2010). 
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COX-2, on the other hand, is induced by secreted cytokines and growth factors and is mainly 
involved in the regulation of inflammatory and proliferative responses. Some studies suggest 
that dysregulation of COX-2-expression may play a role in the development of cancer as this 
has been observed in e.g. colorectal tumors (Sinicrope and Gill, 2004;Tsujii et al., 1997) and 
breast cancer (Ristimaki et al., 2002;Wang et al., 2007b). COX-3, which is a splice variant of 
COX-1, is predominantly expressed in the brain and the heart (Chandrasekharan et al., 2002). 
Its functions, however, remain obscure. Following synthesis, the PGs transcend the plasma 
membrane either by diffusion or active transport (Park et al., 2006) and exert their biological 
actions through the selective binding of high-affinity prostanoid receptors located on the 
surface of the same or nearby cells (Sugimoto and Narumiya, 2007). 
1.4.2 PGE2-EP receptor signaling 
The physiological effects of PGE2 are conveyed through a group of seven transmembrane 
domain G-protein-coupled receptors (GPCRs) called E prostanoid (EP) receptors that are 
divided into 4 subtypes, EP1-4, with unique patterns of expression (Sugimoto and Narumiya, 
2007). The diversity in the cellular outcomes initiated by PGE2 is attributed to its binding 
ratio to the four different receptor subtypes and the sites of action. Each of the EP receptors is 
linked to distinct G proteins and thereby initiates different signaling pathways (Breyer et al., 
2001) (Figure 9). It has been demonstrated that signaling through the EP1 receptor, which is 
coupled to a class of Gq proteins, induces PLC-/ that mediates elevation of the free 
calcium concentration in the cytosol. The EP2 and EP4 receptors, which are both known to 
engage Gs proteins, activate adenylate cyclase (AC) upon ligation and cause the intracellular 
levels of cAMP to rise (Figure 9). Such augmentation of cAMP has been shown to negatively 
influence the immune function of T cells by activating cAMP-dependent protein kinase 
(PKA) type I, leading to phosphorylation of numerous molecules downstream of the TCR 
(Figure 10). Of note, PKA type I has been demonstrated to constitute approximately 75% of 
the total PKA activity in human T cells (Skalhegg et al., 1992). The EP3 receptor, which 
predominantly interacts with Gi proteins, inhibits adenylate cyclase as it becomes activated, 
thereby causing a reduction in intracellular cAMP (Figure 9). The different EP receptors do 
not necessarily interact with only one G protein and may, through the binding of several G 
proteins, influence several different transduction pathways (Sugimoto and Narumiya, 
2007;Breyer et al., 2001). Like other locally acting lipid mediators PGE2 has a short half-life. 
It is rapidly inactivated – within seconds or a few minutes – by the cytosolic enzymes 15-
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ketoprostaglandin 13-reductase and 15-hydroxyprostaglandin dehydrogenase (Funk, 
2001;Legler et al., 2010). 
 
Figure 10. PGE2 inhibits cell proliferation through a cAMP-PKA inhibitory pathway (Skalhegg 
et al., 1992;Vang et al., 2001;Vang et al., 2003). Engagement of the EP2 and EP4 receptors by PGE2 on T 
cells initiate phosphorylation of proteins important in the regulation of a number of different signaling 
pathways, of which the most extensively studied is the one mediated by cAMP through PKA type I 
(Tasken and Aandahl, 2004). Elevation of cAMP leads to activation of PKA type I, which is known to 
phosphorylate a number of proteins involved in TCR signaling. One event extensively studied in the 
laboratory of Prof. Kjetil Taskén is the phosphorylation of the C-terminal Src kinase (Csk) at S364 
(Torgersen et al., 2002;Vang et al., 2001). Phosphorylated Csk is recruited to lipid rafts by Cbp/PAG 
(Brdicka et al., 2000;Kawabuchi et al., 2000). Raft-associated Csk then maintain Lck in its inactive state 
through phosphorylation of its Y505 residue (Vang et al., 2003;Vang et al., 2004), thereby preventing it 
from phosphorylating and activating the -chain of the TCR/CD3 complex (Vang et al., 2001). Thus, 
PGE2 may potentially modulate the activation, differentiation and/or proliferation of T cells. Notably, 
PGE2 may inhibit T cells also in cAMP-independent ways, e.g. by suppressing the release of intracellular 
Ca2+ or inhibiting the activity of Fyn. Adapted from (Torgersen et al., 2002). 
1.4.3 The role of PGE2 in immune regulation 
Since PGE2 can be produced by practically any cell in the body, it has the ability to regulate 
numerous physiological and pathophysiological processes. In Paper I, we aimed to investigate 
signaling networks induced by PGE2 in various lymphocyte subsets, with a special attention 
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to T cell subsets. Accordingly, this section will focus on the role of PGE2 in T cell-mediated 
immunity and tumor biology. 
The production of PGE2 is enhanced during inflammation in response to various 
immunological stimuli such as TNF- and IL-1 (Dayer et al., 1985;Dayer et al., 1986). 
Although monocytes, macrophages, dendritic cells, fibroblasts and vascular endothelial cells 
are known as the main sources of PGE2 in the immune system (Harris et al., 2002;Kalinski, 
2012;Kurland and Bockman, 1978), lymphocytes may also up-regulate COX-2 and produce 
PGE2 upon external stimuli (Iniguez et al., 1999;Mahic et al., 2006;Yaqub et al., 2008). The 
importance of PGE2 as a pro-inflammatory mediator has been emphasized by the clinical 
efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) inhibiting COX either in an 
indiscriminate manner or by selective COX-2 inhibition (coxibs) (Simmons et al., 2004). 
Studies of knock-out mice deficient for the individual EP receptors have additionally revealed 
that PGE2 not only acts as a pro-inflammatory mediator but also exerts anti-inflammatory 
functions (Sugimoto and Narumiya, 2007). In T cells, this effect relies predominantly on the 
EP2 and EP4 receptors (Nataraj et al., 2001). Although there appears to be some redundancy 
between these two receptors, they may contribute to varying extent (Sugimoto and Narumiya, 
2007). 
Dysregulation of COX enzymes has been linked to the pathogenesis of several diseases, 
including a variety of cancers (Greenhough et al., 2009;Wang et al., 2007b). In particular, the 
over-expression of the inducible isoform COX-2 – with increased production of PGE2 as a 
consequence – has been associated with colorectal, pancreatic, lung and breast cancer (Wang 
et al., 2007b). In contrast to these observations, however, a recent study suggested a 
correlation between reduced expression of COX-2 and the development of primary breast 
cancer (Boneberg et al., 2008), implying a more complex role of PGE2 in immune regulation. 
Overproduction of PGE2 by tumor cells has been proposed as one of the strategies tumors use 
to evade anti-tumor immunity. In support of this, administration of antibodies against PGE2 
has been shown to delay tumor growth in mice (Greenhough et al., 2009). The underlying 
mechanisms by which PGE2 prevents efficient anti-tumor immune responses remain poorly 
understood. However, some clues may be gathered from the finding that PGE2 secreted from 
COX-2 over-expressing lung cancer cells significantly induced the expression of FOXP3 in 
human CD4+CD25- T cells, resulting in a Treg phenotype (Baratelli et al., 2005;Sharma et al., 
2005). Along this line, studies in the laboratory of Prof. Kjetil Taskén indicated that iTregs 
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that expressed high levels of COX-2 with subsequently high production of PGE2, exhibited 
suppressive capacity (Mahic et al., 2006;Yaqub et al., 2008). These data suggest that PGE2 
may be responsible for both the acquisition of a Treg phenotype and the suppressive function 
of the resulting iTregs. Furthermore, PGE2 has been implicated in the polarization of the 
immune response towards a Th2-type response that does not favor destruction of tumors. In 
this context, knock-out studies in mice have demonstrated that PGE2, through activation of 
the EP2 and EP4 receptors, suppresses Th1 differentiation (Nataraj et al., 2001) and thereby 
facilitating Th2 responses. The ensuing activation of AC and resulting increase in intracellular 
cAMP leading to activation of PKA have been demonstrated to inhibit signaling mediated 
through the TCR and/or costimulatory molecules such as CD28 (Mustelin and Tasken, 
2003;Chemnitz et al., 2006). Accordingly, the modulatory effects of PGE2 on T cells are 
influenced by the simultaneous stimulation of the cell and the strength of the activation. 
A study aimed at examining how the effect of PGE2 was modulated by varying concentrations 
of stimulatory anti-CD28 antibodies (Yao et al., 2009), showed that in the presence of weak 
CD28 stimulation PGE2 suppressed Th1 differentiation in a concentration-dependent manner, 
supporting earlier observations (Betz and Fox, 1991;Harris et al., 2002). Surprisingly, 
however, in the presence of stronger CD28 stimulation PGE2 facilitated Th1 differentiation. 
This effect was mediated primarily through the EP4 receptor, which instead of inducing 
intracellular cAMP levels led to activation of the PI3K pathway (Yao et al., 2009), as 
previously observed for EP4 signaling in other biological systems (Fujino et al., 2003;Fujino 
and Regan, 2006). However, the relevance of this dual effect of PGE2 on Th1 differentiation 
remains to be verified in vivo. Examination of the effect of PGE2 on the differentiation of 
human CD4+ T cells have also shown a dose-dependent facilitation towards Th17 cells in the 
presence of the cytokines IL-23 and IL-1 (Boniface et al., 2009). Supporting this 
observation, another study showed that PGE2 together with IL-23 synergistically facilitated 
the expansion of Th17 cells from the memory (CD4+CD45RO+) T cell population. 
Unfortunately, the experimental setup in this study was not designed to detect the influence of 
PGE2 on differentiation of naive T cells (CD4+CD45RO-) (Chizzolini et al., 2008). 
Importantly, the effects described above were mediated through both the EP2 and EP4 
receptors resulting in the classical increase in intracellular cAMP levels. Overall, these 
observations indicate that PGE2 in combination with other stimuli differently influence the 
differentiation of Th subsets, resulting from the fact that the EP2 and EP4 receptors may 
induce several distinct signaling pathways. 
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Investigating signaling differences between cell subsets, discrepancies in signaling pathways 
are desirable as these may represent potential targets for therapeutic intervention in disorders 
with deregulated signaling responses in one of the subsets. Although extensive research has 
been carried out in order to reveal the mechanisms underlying the inhibitory role of PGE2 in T 
cells, our knowledge are still limited and further examinations of these mechanisms are 
warranted. Previous work has identified roles of PGE2 in modulating proliferation, apoptosis 
and cytokine production in T cells (Harris et al., 2002). Furthermore, PGE2 has been shown to 
suppress B cell function and act as an anti-inflammatory mediator on innate immune cells like 
granulocytes, monocytes and NK cells. Consequently, PGE2 and the signaling pathways 
induced upon engagement of the individual EP receptors may represent promising targets for 
reversing immune suppression and preventing tumors from subverting the immune system. 
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2 Aims of the study 
While both B- and T cell activating signal pathways and PGE2 signaling has been extensively 
studied over many years, new technologies now allow the parallel analysis of many signaling 
readouts with the possibility of achieving more of a systems understanding of signal 
propagation in these cells. Furthermore, single-cell analysis allow for mapping signaling 
responses in specific subsets of immune cells. The aims for the work in the present Thesis, 
based on earlier work and focus in the group, were to: 
1. Map phosphorylation-based signaling networks in response to PGE2 in distinct T cell 
subsets. 
2. Study the signaling patterns upon TCR triggering in the presence of CD28 and/or CD2 
costimulation in different T cell subsets, i.e. naive and effector/memory CD4+ and 
CD8+ T cells as well as rTregs and actTregs. 
3. As a consequence of our findings when addressing aim number 2, determine the 
influence of the Mek-Erk signaling pathway in up-regulating the Treg-specific 
transcription factor FOXP3 and controlling the suppressive capacity of rTregs. 
4. Examine the interaction between the adaptor protein PAG and the Src kinase Lyn in B 
cells and its effect on B cell signaling. 
5. Elucidate the regulatory potential of PAG in early BCR signaling in both normal and 
transformed B cells. 
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3 Summary of Results 
Paper I: “High-resolution mapping of prostaglandin E2-dependent signaling networks 
indentifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells” 
In this study, we investigated PGE2 signaling networks in lymphocytes by a novel 
combination of a quantitative MS-based phosphoproteomic approach, kinase prediction and 
high throughput phospho-flow cytometry. Using temporal quantitative phosphoproteomic 
MS, we monitored 247 unique phospho-sites on about 200 proteins regulated in response to 
PGE2 treatment. Furthermore, by combining these phosphoproteomic MS data with stringent 
kinase predictions, we were able to predict signaling kinase networks for more than 20 
kinases, with PKA as the strongest node and CAMKII and PKB/Akt as supplementary nodes. 
Based on these results we were able to select a series of phospho-epitope-specific antibodies, 
which were used in a high throughput phospho-flow cytometry-based method. A detailed 
analysis of naive and effector/memory CD4+ and CD8+ T cell populations revealed 
constitutively augmented PKA activity in effector/memory cells, especially in CD8+ T cells. 
Moreover, the higher activation status of PKA in these cells raised the activation threshold, 
possibly providing a mechanism for avoiding non-specific T cell activation. 
Paper II: “T cell signaling network analysis reveals distinct differences between CD28 and 
CD2 costimulation responses in various subsets and in the MAPK pathway between resting 
and activated regulatory T cells” 
In order to unravel the signaling signatures of different human T cell subsets upon various T 
cell stimuli, the phosphorylation status of 18 signaling proteins was studied at six different 
time points following TCR triggering in the absence or presence of CD28 and/or CD2 
costimulation. The combined use of phospho-flow cytometry and fluorescent cell barcoding 
provided a high-resolution signaling map, which served as the basis for our studies. 
Compared to effector/memory T cells, naive T cells displayed stronger activation of proximal 
signaling molecules after TCR triggering alone, while for distal phosphorylation events like 
pErk and pS6-Rp the situation was reversed. CD28 costimulation initiated the signaling 
events required for proper NF-B activation, while activation of CD2 promoted signaling 
through S6-Rp. Analysis of signaling patterns in resting regulatory T cells (rTregs, 
CD4+CD45RA+Foxp3+) and activated regulatory T cells (actTregs, CD4+CD45RA-Foxp3++) 
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revealed that while rTregs had low basal, yet inducible Erk and Akt activity, actTregs 
displayed high basal Erk phosphorylation and little or no Akt activation. Interestingly, the use 
of Mek inhibitors to block Erk activation inhibited the activation-dependent up-regulation of 
FOXP3 in rTregs as well as their transition to actTregs with increased suppressive capacity. 
Paper III: “Modulation of proximal signaling in normal and transformed B cells by 
transmembrane adaptor Cbp/PAG.” 
The SH3 binding sites for Lyn in PAG were identified using peptide binding arrays and Lyn 
SH3-GST protein. We observed that Lyn preferentially bound to the PRD1 domain in PAG 
and that this interaction was crucial for efficient phosphorylation of PAG by Lyn in vitro. We 
studied the BCR triggered responses in normal and transformed cells using both western 
blotting and phospho-flow cytometry, and observed that siRNA mediated knock down (KD) 
of PAG gave enhanced and prolonged activation of proximal BCR signaling in normal human 
B cells, but not in the Raji line of human Burkitt’s lymphoma (BL) B cells with over-
expressed PAG. Moreover, we examined the impact on BCR signaling of a PAG variant that 
contained two enhanced PRD motifs for Lyn binding (PAG**). In contrast to low expression 
of PAG, high expression resulted in decreased proximal BCR signaling, which was reinforced 
by increased association of Lyn with PAG. This effect appears to be linked to Csk activity as 
transient transfection of a PAG construct lacking binding sites for Csk resulted in stronger 
early BCR responses. In summary, our data indicate that PAG through interaction with the 
SH3 domain of Lyn and increased recruitment of Csk negatively regulates proximal BCR 
signaling in normal human B cells, at least in vitro. 
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4 Discussion 
In the Introduction, I have provided an overview of the cellular organization of the immune 
system and the signaling responses elicited in both B- and T cells upon activation. I have 
outlined some of the functional importance of the systems studied in order to give background 
information relevant to the articles included in this Thesis and emphasize the unexplored 
potential of this research field. In the Discussion, I will go more deeply into the findings in 
each of the three individual projects and discuss them in separate chapters. Finally I will 
round off by discussing phospho-flow cytometry, which has been used as an investigation tool 
in the studies presented here, and compare this method with three other commonly used 
methods for signaling studies. 
4.1 System views of PGE2 signaling networks 
The immunological research strategies have changed over the last decade from being 
performed based on hypotheses that rely on earlier results or published work by other 
investigators to utilization of high-throughput methods for investigating features of cell 
systems in an unbiased manner in order to produce new hypotheses (Benoist et al., 2006). In 
this context, proteomic studies are essential for the development of quantitative models by 
providing information about the cellular constituents at a molecular level as well as the 
biochemical states of proteins. A cell will respond to external stimuli through a complex 
interplay between several hundreds to thousands of proteins, ultimately instructing the 
secretion of cytokines specific for that particular cell, initiating cell proliferation and 
differentiation, or even committing the cell to apoptosis. Proteomic analysis provides a 
snapshot of the overall protein expression in a cell population under certain experimental 
conditions. In Paper I, we took advantage of a multipronged strategy with phosphoproteomic 
mass spectrometry (MS), kinase prediction algorithms and phospho-specific flow cytometry 
in order to study signaling networks induced by PGE2 in primary human T cells. Indeed, 
temporal maps of PGE2 signaling networks in healthy individuals may contribute to revealing 
aberrant responses to PGE2 with relevance to pathological processes. 
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4.1.1 Phosphorylation-based signaling networks regulated by PGE2 
Phosphorylation-based signaling networks are defined by an inter-relationship between 
substrates of various effector kinases and phosphatases. The phosphorylation of kinase 
substrates is a highly transient process due to the rapid interplay between kinases and 
phosphatases. Hence, strategies employed to study phosphorylation-based signaling networks 
need to provide sensitive and reliable readouts to capture dynamic changes (Tan and Linding, 
2009). In Paper I, we initially investigated the temporal regulation of PGE2-induced signaling 
processes by utilizing a sensitive, high-throughput approach based on quantitative MS. As MS 
is not intrinsically quantitative (Choudhary and Mann, 2010), the introduction of chemical 
tags by triplex stable isotope dimethyl labeling of peptides allowed us to study 3 different 
time-points simultaneously, enabling investigation of temporal regulation (Boersema et al., 
2008). Since phosphorylated proteins are present in small amounts and constitute only a 
minority of the proteome, the peptides resulting from multiple digestions were enriched after 
isotope labeling using a procedure involving sub-fractionation via strong cation exchange 
(SCX) and, subsequently, an optimized chromatographic technique based on complex 
formation between the phosphate groups and the metal oxide TiO2 (Pinkse et al., 2008). This 
approach led to the identification of 796 triple-labeled phosphopeptides where 
phosphorylation of 247 of these, originating from 207 different phosphoproteins, appeared to 
be regulated by PGE2 in primary T cells within one hour of stimulation. Although different 
patterns of temporal regulation were observed, the majority of the regulated phosphopeptides 
displayed considerably increased phosphorylation levels after 10 minutes of stimulation, 
which declined to near basal levels within 60 minutes, corresponding to the kinetics observed 
for PKA substrates containing the RRXpS/pT phosphorylation site. 
Many of the discovered phosphorylation sites reported in Paper I were previously unknown 
mediators of PGE2 signaling. In order to associate the 247 identified phosphorylation sites to 
their respective kinases and thereby reconstruct signaling networks regulated by PGE2, we 
used 3 different algorithms for kinase prediction based on our MS data (Obenauer et al., 
2003;Linding et al., 2008;Gnad et al., 2011). The combined results of the MS-based 
phosphoproteomics and kinase prediction algorithms highlighted PKA as one of the main 
kinases for the identified phosphorylation epitopes, along with CAMKII, PKB/Akt and 
GSK3. Based on the fact that PGE2 mainly exerts its effects in T cells through stimulation of 
the EP2 and EP4 receptors, it was not a surprise that PKA was the kinase associated with a 
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majority of the phosphorylation sites. However, prediction of CAMKII, a known downstream 
mediator of EP1, and PKB/Akt, which is downstream of EP3, suggest that these receptors may 
also be operative in T cells. Although the algorithms employed in our study were based on 
sets of kinase phosphorylation sites identified by high-accuracy MS data, they cover only a 
minor part of the human proteome (Obenauer et al., 2003;Linding et al., 2008;Gnad et al., 
2011). Moreover, the consensus sequences recognized by different kinases as predicted in the 
data sets underlying the algorithms used in such kinase predictions have considerable overlap, 
meaning that several of the predicted kinases phosphorylate either identical or similar 
phosphorylation sites. For these reasons, prediction of kinases based on bioinformatics 
analysis of proteomics data should ideally be verified experimentally. To remove some noise, 
we initially chose to include only kinases predicted by at least two of the algorithms included, 
and next set out to verify that the remaining kinases were in fact activated by PGE2, either by 
looking at the same substrates or other readouts in the same pathways. Phospho-specific flow 
cytometry was used for this purpose, allowing the study of dynamic changes in a set of 
selected phosphorylation sites where phospho-specific antibodies were available. 
Using the phospho-flow approach, we confirmed a concentration-dependent temporal 
activation of PKA in response to PGE2 treatment. We also verified PGE2-induced 
phosphorylation of GSK3. Interestingly, in this respect, GSK3 phosphorylation at S21 
exhibited a kinetic profile similar to PKA substrates with the RRXpS/pT phosphorylation site. 
In human embryonic kidney (HEK) 293 cells, PKA has previously been demonstrated to 
complex with GSK3 and inactivate its kinase activity by phosphorylating the S21 residue 
(Fang et al., 2000). The predicted GSK3 substrates recorded in our MS dataset show 
decreased phosphorylation in response to PGE2, which is consistent with an inhibitory role of 
PKA on GSK3 activity, by phosphorylation of S21, also in T cells. This indicates a direct 
crosstalk between PGE2, PKA and GSK3 signaling in primary human T cells. GSK3 is a 
multi-functional serine threonine kinase that is involved in numerous cellular processes 
including glycogen metabolism and glucose homeostasis, proliferation and regulation of gene 
expression, as well as development of tumors and neuronal function (Rayasam et al., 2009). 
As for PGE2 signaling, the activity of GSK3 has been linked to a variety of diseases including 
inflammation and cancer. Hence, further investigations are required to resolve the functional 
implications of the observed PGE2-PKA-GSK3 signaling pathway in primary T cells from 
healthy individuals. 
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Although strongly suggested by the kinase prediction algorithms, little or no changes in 
phosphorylation were detected for CAMKII or PKB/Akt upon a 60-minute time course of 
PGE2 stimulation. Absence of CAMKII phosphorylation in our phospho-flow setup was 
further supported by the absence of intracellular calcium flux in response to PGE2 treatment. 
Together, these results indicate that the two kinases were over-represented in the datasets 
generated by the algorithms. In fact, some of the phosphorylation sites identified for CAMKII 
and PKB/Akt overlap with sites identified for PKA and could therefore in reality be PKA 
targets, meaning that they were falsely attributed to CAMKII and PKB/Akt by the algorithms. 
On the other hand, nine unique phosphorylation sites were identified for CAMKII and six for 
PKB/Akt, suggesting that their kinase activities in response to PGE2 treatment were below the 
detection limit of the phospho-flow technique applied in our study. 
Collectively, our data indicate that PKA is the central node of PGE2-regulated signaling 
networks in primary T cells, an effect that is known to be mediated through stimulation of the 
EP2 and EP4 receptors. These results are in accordance with a previous report published by 
Boniface et al., which demonstrated that both of these receptors are highly expressed in naive 
human CD4+ T cells (Boniface et al., 2009). In comparison, the expression levels of the EP3 
receptor were found to be quite low whereas the EP1 receptor appeared to be absent in this 
particular cell subset. The main advantage of the approach introduced in Paper I is its ability 
to provide a global view of regulated signaling networks in primary cells as opposed to most 
quantitative MS-based signaling studies of today, which have been performed using 
immortalized cell lines (Choudhary and Mann, 2010). Given the fact that phosphorylation-
based signaling networks observed in cell lines may not be representative of those in normal 
cells, proteomic studies of primary cells are highly warranted. The dataset presented in Paper 
I reveals the complexity of PGE2-induced signaling responses in human peripheral T cells and 
may serve as a valuable starting point for the development of new hypotheses regarding the 
role of PGE2 in various disease contexts such as inflammation and tumor-immunity. 
4.1.2 Detection of subset-specific PKA-regulated signaling effects 
In our phosphoproteomic dataset from the initial MS study reported in Paper I, we identified a 
series of previously uncharacterized PGE2-regulated phospho-sites, some of which have been 
reported to act downstream of the TCR (Torgersen et al., 2008). Specifically, new 
phosphorylation sites in CARMA1, PLC, Wiskott-Aldrich syndrome protein-interacting 
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protein, VASP, GADS, nuclear factor of activated T cells cytoplasmic 2, Fyn binding 
protein/adhesion and degranulation promoting adapter protein, and Nck were identified in our 
study. Considering that PKA was identified as one of the main activated signaling nodes in 
the PGE2-regulated signaling network, we proposed that PKA might bridge PGE2 stimulation 
to these downstream TCR signaling events in primary T cells. In Paper I, this hypothesis was 
explored in distinct subsets of lymphocytes by the use of phospho-flow. 
Our phospho-flow analyses revealed a reduced basal phosphorylation of the -chain in 
effector/memory subsets of both CD4+ and CD8+ T cells as compared to their naive 
counterparts. This finding appeared to depend on elevated PKA type I activity as the reduced 
-chain phosphorylation was reversed by PKA type I inhibitors. Notably, this effect was most 
prominent in CD8+ effector/memory T cells. Despite differential activities of PKA in naive 
and effector/memory T cells, pretreatment with PGE2 prior to TCR stimulation significantly 
inhibited -chain and Slp-76 phosphorylation in either subset. These results are in agreement 
with previous observations in that PGE2 appears to be implicated in PKA type I-mediated 
inhibition of TCR signal transduction (Vang et al., 2003). Thus, they support the predominant 
paradigm in ascribing an inhibitory role to PKA type I in the context of T cell activation. 
As described in the Introduction, naive and effector/memory T cells differ from each other in 
how they respond to antigens. Although it is well established that effector/memory CD4+ and 
CD8+ T cells respond more rapidly and efficiently to recall stimulation by the same antigen 
(Croft et al., 1994;Horgan et al., 1990;Iezzi et al., 1998;Luqman and Bottomly, 1992;Kaech et 
al., 2002), the underlying molecular mechanisms for these differences remain unclear. In this 
respect, the differences in basal PKA-substrate phosphorylation levels between naive and 
effector/memory T cells reported in Paper I might represent one biochemical mechanism that 
contributes to the observed differences in activation threshold. Still, as our study did not relate 
the observed phosphorylation events to actual immune responses in vivo, we can only 
speculate on their biological relevance. Interestingly, however, Conche et al. recently 
demonstrated a transient increase in PKA activity following adhesion-induced T cell priming 
(AITCP), which reduced the activation threshold and thereby facilitated antigen recognition 
(Conche et al., 2009). This is in contrast to the established idea that PKA serves to inhibit T 
cell activation through Csk (Vang et al., 2001), but may be explained either by differences in 
time kinetics (the effect reported by Conche et al. is fast and short-lived) or by the 
concomitant activation of Erk. Thus, the elevated levels of PKA observed in effector/memory 
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T cells may not only reduce proximal signaling events as described above, but could also 
increase the activity of Erk as a way of rendering the cells more sensitive to true antigenic 
stimulation. In line with these findings, an elevated basal phosphorylation level of Erk in 
effector/memory T cells was observed in Paper II. Accordingly, elevated PKA activity may 
be seen as a way of inhibiting inappropriate activation of effector/memory cells, while 
elevated Erk activity facilitates activation when proper antigen-binding take place. Thus, high 
basal phosphorylation of PKA might facilitate signal transduction upon antigen binding in 
antigen-cognate cells through activation of Erk, while at the same time inhibiting TCR 
signaling resulting from stimulation by for instance PGE2. To our knowledge, Paper I is the 
first report to demonstrate differential basal PKA activity between naive and effector/memory 
T cells. 
4.2 Signaling networks in T cell activation 
T cell signaling has been extensively studied for many years and the various signaling 
pathways involved are well characterized. However, despite the fact that T cell signaling is a 
much researched subject, new discoveries are still being made and added to the web of 
knowledge. Furthermore, systems understanding of the process is still developing and there is 
a need for an overview of how distinct signaling pathways integrate and crosstalk in order to 
generate signaling networks in T cells. In addition, the increasing number of different T cell 
subsets being defined (as described in the Introduction) and the possibility of signaling 
differences between these subsets, warrant subset-specific signaling analyses to link signaling 
activity to functional properties of individual subsets of T cells. Paper II contributes to the 
understanding of both subset-specific signaling and how costimulation through CD2 and/or 
CD28 contribute to signal intensity and affect signal integration in functionally defined T cell 
subsets, as will be discussed in the following sections. 
4.2.1 Signaling capabilities of the CD28 and CD2 coreceptors 
In agreement with previous observations, the experiments presented in Paper II revealed an 
augmentation-effect of CD28 costimulation in all the defined subsets tested, both naive and 
effector/memory CD4+ and CD8+ T cells. In addition, we found that the signaling responses 
in these subsets were even stronger with concomitant stimulation through the CD2 coreceptor. 
Although TCR signaling in the presence or absence of CD28 costimulation in conventional 
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naive/memory CD4+ T cells is already well characterized (Acuto and Michel, 2003;Rudd et 
al., 2009) and CD2 though to be redundant versus CD28 (Green et al., 2000), we found 
distinct differences in signaling following CD28 and CD2 costimulation and between several 
distinct subsets of CD4+ and CD8+ T cells that have not been observed earlier. Notably, these 
signaling effects are presented with a higher resolution than previously published due to the 
power of the phospho-flow method, which gives information of signaling responses at the 
level of single cells. 
Our study of the costimulatory effect of CD28 presented in Paper II showed that stimulation, 
through this coreceptor compared to TCR stimulation alone, induces higher levels of 
phosphorylation of many of the signaling molecules tested, including -chain 
phosphorylation. These observations are consistent with data previously published by Andrew 
Shaw and colleagues, who demonstrated that Lck via the SH3 domain binds CD28 and gets 
activated by stimulation through this coreceptor (Holdorf et al., 1999). In contrast, our results 
are not compatible with the model proposed by Acuto and Michel suggesting that CD28 
signaling first converges with the classical TCR signaling pathway at the level of Slp-76 and 
PLC1 and does not involve Lck (Michel et al., 2001). These differences may be explained by 
the fact that our observations were made in primary T cells, whereas Michel and Acuto’s 
model was based on experiments from Jurkat cells, a transformed human leukemia T cell line 
that we now know carries a mutation in the PTEN gene making the PI3K pathway 
constitutively active (Shan et al., 2000) and which does not require costimulation in order to 
become activated. Hence, these observations may not reflect the true function of CD28 in 
primary human T cells. Furthermore, while earlier research mainly reflect signaling responses 
of the total CD4+ T cell population, the technology now allows for analysis of subset-specific 
signaling effects. As the data presented in Paper I and II indicate, signaling responses in 
heterogeneous populations may cancel each other out due to variations in signaling effect and 
amplitude between the various subsets included in the analysis, an observation also reported 
by  Adachi and Davis (Adachi and Davis, 2011). This could cause differences when findings 
in the older literature examining CD3+ or CD4+ T cell populations are compared to the 
observations made with the present technology. 
As discussed in the Introduction, knock-out studies in mice of either the CD28 or CD2 
coreceptors or both have indicated that at least some degree of costimulation is necessary in 
order to avoid anergy and ensure proper T cell activation for further differentiation (Green et 
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al., 2000;Sasada and Reinherz, 2001;Shahinian et al., 1993). These studies also suggest the 
existence of functional redundancy as loss of CD28 can be compensated for by CD2 and vice 
versa. The results presented in Paper II demonstrate that engagement of the CD28 coreceptor 
induces unique signals essential for NF-B activation, whereas CD2 costimulation mainly 
enhances TCR-mediated signaling responses. A central issue raised by these observations is 
how CD2 compensates for its lack of ability to properly activate NF-B, if the idea of 
redundancy is correct. The data gained from our study do not provide an answer to this 
question and further investigation is required to give a definitive answer. Nevertheless, we 
observed an augmented phosphorylation of proximal TCR signaling events, such as 
phosphorylation of the -chain and activation of ZAP70, both Lck-mediated processes, in 
response to CD2, CD28 or combined CD2/CD28 costimulation. Accordingly, our data 
indicate that both coreceptors amplify early TCR signaling. However, the signaling responses 
to CD2 and CD28 appear to diverge downstream where different signaling responses are 
observed. Our data therefore suggest that CD28 and CD2 may play distinct roles in T cell 
activation even though they are largely able to compensate for the lack of the other. One 
explanation to this may be that both coreceptors function as amplifiers of TCR signaling and 
that they separately and in the absence of the other still are able to reduce the activation 
threshold to a sufficient level for a productive T cell activation response to occur. 
The present knowledge of the signaling events induced in response to CD2 engagement is 
limited and further examination is required in order to evaluate the exact functional role of 
CD2 in T cell activation. Although signaling by CD28 is more extensively studied, the exact 
biochemical events it mediates remains to be fully understood and it is still debated whether 
CD28 support TCR signaling only qualitatively or if it also induces separate signaling 
pathways (Acuto and Michel, 2003;Rudd et al., 2009). Our findings strongly suggest that 
CD28 in addition to amplifying TCR signaling also supports T cell activation qualitatively by 
specifically inducing the activation of NF-B. This observation is supported by a recent 
publication demonstrating that CD28, in an Lck-dependent manner, triggers a unique 
signaling pathway that involves recruitment and binding of PKC to the cytoplasmic tail of 
CD28 at the IS, which ultimately leads to efficient NF-B activation (Kong et al., 2011). 
Previous studies by several investigators have provided convincing evidence that CD28 
ligation indeed specifically regulates the NF-B pathway and associated genes (Kane et al., 
2002;Takeda et al., 2008;Tuosto, 2011), although the necessity of concomitant stimulation 
through the TCR remains controversial. Some of these studies have demonstrated that a PI3K-
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Akt pathway may contribute to the connection between CD28 and NF-B (Tuosto, 2011). Our 
study, however, demonstrates that activation of Akt did not show the same dependency on 
CD28 stimulation as the activation of NF-B did. We therefore hypothesize that signaling 
molecules other than Akt are essential for bridging CD28 stimulation to NF-B activation, 
although our data do not exclude the possibility that the increased CD28-mediated activation 
of Akt observed in the naive subsets may enhance the activity of NF-B. In support of these 
notions, a number of earlier studies have shown that Akt is not a critical mediator for efficient 
TCR/CD28-mediated NF-B activation, but instead appears to be an important regulator for 
the strength and/or duration of its activation (Tuosto, 2011;Takeda et al., 2008;Narayan et al., 
2006). 
4.2.2 Signaling profiles of naive and effector/memory T cells 
Previous studies of signal transduction in human T cells have mainly been carried out in 
conventional or naive CD4+ T cells due to insufficient amounts available for biochemical 
analysis of memory cells and especially of CD8+ T cells. However, recent progresses enabling 
flow cytometry analysis of intracellular signaling responses have contributed to emerging 
knowledge of the biochemical changes induced also in less prevalent subsets. In Paper II, we 
revealed signaling differences between naive and effector/memory subsets of CD4+ and CD8+ 
T cells. Generally, we observed a stronger phosphorylation level in naive cells compared with 
effector/memory cells for proximal TCR-signaling molecules (e.g., the -chain, ZAP70, and 
Slp76) upon activation. These findings are supported by earlier observations in primary 
human CD4+ T cells (Hall et al., 1999). By contrast, the opposite phosphorylation pattern was 
found for more downstream signaling mediators, e.g. Erk and S6-Rp. These differences were 
identified in both CD4+ and CD8+ T cells, although the signals induced in CD8+ T cells 
overall were reduced compared to those of CD4+ T cells. 
Adachi and Davis demonstrated in a recent publication that human peripheral naive and 
effector/memory CD4+ T cells diverge in their initial response to activation at the level of Erk 
and p38 (Adachi and Davis, 2011). Interestingly, their data showed that TCR-mediated Erk 
phosphorylation is preferentially induced in naive cells, whereas p38 activation is 
predominantly observed in effector/memory cells after short-term stimulation (two minutes). 
Consistent with these findings, we observed a slightly lower responsiveness of p38 in naive 
cells compared with effector/memory cells. However, more importantly, we observed a 
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reduced ability of effector/memory cells to become Erk phosphorylated upon activation. 
Examination of the resting signaling states between these two subsets revealed, as mentioned 
previously, an augmented constitutive phosphorylation level of Erk in the effector/memory 
subsets. This high basal level of phospho-Erk might contribute to the stringent regulation of 
signal transduction observed in these cells. Adachi and Davis reported a negative link 
between activation of Erk and facilitated propagation of more downstream signaling events, 
which is compatible with this notion (Adachi and Davis, 2011). Further, we observed optimal 
Erk activation in effector/memory cells only when both coreceptors were stimulated 
simultaneously. Accordingly, under proper stimulatory conditions it might be that this high 
basal phosphorylation level of Erk in resting effector/memory T cells makes these cells better 
positioned to efficiently process downstream signals. 
Despite differential regulation of Erk, all subsets in our study exhibited equal basal 
phosphorylation levels and proper induction of the -chain, ZAP70, and Slp-76, although the 
levels were slightly reduced in the effector/memory cells. Adachi and Davis, on the other 
hand, demonstrated that differential Erk phosphorylation was mediated through the activation 
of Slp-76 as TCR-triggered naive CD4+ T cells got strongly phosphorylated whereas the 
effector/memory cells did not. This distinct coupling of signaling appeared to be independent 
of ZAP70, which was equally activated in both subsets (Adachi and Davis, 2011). In contrast, 
Farber et al. demonstrated earlier a considerably higher induction of ZAP70 in naive murine 
CD4+ T cells compared to the corresponding effector/memory population (Farber et al., 
1997). However, Farber and colleagues only investigated CD3-induced signaling responses 
that are known to induce anergy. Comparison of the differential effects elicited by the 
different stimulatory conditions in our study revealed that costimulation was essential for 
optimal phosphorylation of ZAP70 in all subsets except the naive CD4+ T cells. Hence, the 
differences in observations may be due to different stimulatory conditions being used. 
Alternatively, these differences reflect disparity between human and murine systems or 
simply occur as a result of differences in sensitivity of the techniques used for detection. 
Taken together, our data reveal several interesting and novel features of the intracellular 
signaling capacities of naive and effector/memory CD4+ and CD8+ T cells. Our findings 
suggest that the differential activation responses displayed by these two subsets occur distally, 
as the most prominent differences in signaling were detected at the level of Erk. However, our 
study focused on immediate and early effects of T cell activation (from minutes to one hour 
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post-activation). It is therefore reasonable to expect that these signaling responses may be 
modulated during long-term stimulation by integration of other signals initiated for instance 
by auto- or paracrine effects of cytokines secreted during the course of activation. 
Furthermore, we cannot rule out that other regulatory phosphorylation sites not examined may 
play important roles in controlling the distinct functions and activation requirements of naive 
and effector/memory T cells.  Nonetheless, our data indicate that Erk may be a central 
regulator of the immediate early signaling responses that functionally distinguish these cells. 
4.2.3 Signaling in different Treg subsets, rTregs versus actTregs 
As described in the Introduction, human FOXP3+ T cells constitute a heterogeneous 
population of both non-suppressive and suppressive T cells with distinct functional properties 
(Fritzsching et al., 2006;Miyara et al., 2009;Seddiki et al., 2006;Valmori et al., 2005). For an 
intervention to be effective in the treatment of immunological disorders where Tregs have 
clinical impact, manipulation of distinct subpopulations may be necessary. As the FOXP3+ 
subsets are quite recently defined, little is known about the underlying molecular 
characteristics that functionally differentiate them. In Paper II, we attempted to characterize 
and compare intracellular signaling cascades induced in these subsets upon activation with a 
main focus on the distinction between rTregs and actTregs. 
Comparison of the signaling responses induced in rTregs versus actTregs in Paper II revealed 
a clear difference in the activation response of Akt. Whereas rTregs show a robust induction 
of phospho-Akt upon T cell activation, actTregs displayed little or no Akt phosphorylation. 
Interestingly, the phosphorylation state of Erk was constitutively elevated in actTregs to a 
level higher than that observed for effector/memory T cells. As a result of this high basal 
level, diminished activation response of Erk was detected in the actTregs in comparison to 
that found in the rTreg population. A previous study, designed to compare the signaling 
responses between conventional CD4+CD25- T cells and CD4+CD25+ Tregs, revealed a 
significantly lower induction of Akt by the co-engagement of TCR and CD28 in the Treg 
population (Crellin et al., 2007). As the Tregs here were defined as the CD4+CD25high T cells, 
these cells most probably correlate to the actTregs in our study and hence are in line with our 
observations. However, in contrast to our data, Crellin et al. did not detect any differential 
phosphorylation response for Erk. As the distinction between CD25low and CD25high is 
somewhat arbitrary, these differences may be due to the composition of the T cell population 
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analyzed by Crellin et al., which could contain both rTregs and cytokine-producing FOXP3+ 
T cells. The functional importance of the observed differential signaling responses between 
rTregs and actTregs was examined in Paper II as described in the following section. 
4.2.4 Regulation of Foxp3 expression and suppressive function 
One of the main differences in phenotype characteristic between rTregs and actTregs is the 
expression level of FOXP3. We therefore hypothesized that the FOXP3 level influences the 
differential activation responses observed in these subsets. Although it is well documented 
that FOXP3 is one of the key regulators that preserve immune tolerance, the detailed 
molecular mechanisms governing its induction have just begun to be discovered (Josefowicz 
et al., 2012;Merkenschlager and von, 2010). Given the dominant role of Tregs in the 
maintenance of immune homeostasis, it is beneficial for development of new therapeutic 
strategies to gain more knowledge about the signaling pathways that either positively or 
negatively controls their function. 
As rTregs are considered to be functional precursors of actTregs (Fritzsching et al., 2006;Ito 
et al., 2008;Miyara et al., 2009), we wanted in Paper II to identify signaling factors that might 
control up-regulation of FOXP3 in stimulated rTregs. In light of previous reports that have 
demonstrated that Akt activation dampened Foxp3 induction (Delgoffe et al., 2009;Harada et 
al., 2010;Haxhinasto et al., 2008;Sauer et al., 2008), it was somewhat surprising that our 
results indicated an independent role of Akt signaling in this respect. However, all of these 
studies have characterized the signaling effect of Akt in the differentiation process of murine 
Tregs and therefore do not necessarily mirror the functional role of Akt in human T cells. In 
addition, these studies have explored the mechanisms that control Foxp3 expression in 
peripheral CD4+CD25- T cells (Delgoffe et al., 2009;Harada et al., 2010;Haxhinasto et al., 
2008;Sauer et al., 2008), which may respond differently than natural committed rTregs. In 
line with this notion, one of these studies demonstrated a differential sensitivity between 
conventional and regulatory T cells in the activation of Akt, as nTregs appeared to be resistant 
to Akt-dependent inhibition of Foxp3 expression (Haxhinasto et al., 2008). This is supported 
by findings reported by Rubtsov and colleagues, which demonstrated a stable Foxp3 
expression in mature murine Tregs even in the presence of immunological challenges 
(Rubtsov et al., 2010). Despite apparent lack of regulation of FOXP3 expression in our study, 
pretreatment with Akt-inhibitor upon subsequent stimulation of rTregs markedly impaired 
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their suppressive capacity, suggesting that defect Akt signaling inhibits the suppressive ability 
of these cells in a FOXP3-independent manner. This independent role of FOXP3 regulation in 
suppressive function has earlier been reported in human CD4+CD25high Tregs (Crellin et al., 
2007). However, the opposite observation with abrogation of suppression by activation of Akt 
was demonstrated in this report. Combined with our data, these findings suggest that Akt 
signaling may play a different role in rTregs versus actTregs, which may be reflected by the 
distinct activation responses observed in Paper II. 
Based on the differential phosphorylation response of Erk between rTregs and actTregs, it 
was interesting to note that FOXP3 inducibility in rTregs appeared to be profoundly 
abrogated by perturbation of the Mek-Erk signaling pathway. Moreover, inhibition of this 
pathway reversed the ability of pre-activated rTregs to exert their suppressive function, 
suggesting that a Mek-Erk-dependent induction of FOXP3 is crucial for full development of 
these cells into actTregs. A recent publication by Beyer et al. showed that the Foxp3-
controlled repression of the transcription factor SATB1, which acts as a chromatin organizer 
known to be involved in development and activation of T cells (Alvarez et al., 2000), is 
required for the suppressive function of murine Tregs (Beyer et al., 2011). This FOXP3-
mediated inhibition of SATB1 activity appeared to be due to suppression of transcriptional 
programs that direct differentiation of human effector T cells (Beyer et al., 2011), indicating 
that the integrity of Tregs is dependent on continuous inhibition of effector T cell function. 
Interestingly, manipulation of human Tregs to ectopically express high levels of SATB1 led 
to reversal of FOXP3-mediated repression and induction of inflammatory effector cytokines 
(Beyer et al., 2011). This finding may in part explain why conventional T cells that 
temporarily express lower levels of FOXP3 upon early activation do not gain suppressive 
function. An alternative model for the terminal differentiation of peripheral T cells has earlier 
been proposed by Pan et al. (Pan et al., 2009). In this report, they demonstrated that the 
transcription factor Eos in primary murine Tregs directly interact with Foxp3 in order to 
repress genes associated with differentiation of effector T cells (Pan et al., 2009). Thus, 
together with our observation that elevated basal Erk activation is maintained only in the 
actTregs, it is tempting to speculate that differentiation of rTregs into actTregs involves a shift 
in Mek-Erk signaling that is necessary in order to keep the level of FOXP3 in actTregs high 
and confer these cells with unique suppressive capabilities in a similar manner as observed for 
the transcription factors Eos and SATB1. Mechanistically, the selective TCR and coreceptor 
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coupled activation of Mek-Erk and Akt signaling in rTregs might prevent untimely initiation 
of Treg-mediated suppression in the early phase of an immune response. 
4.2.5 Controlling immune responses by targeting Tregs 
Based on the key role of Tregs in the maintenance of peripheral tolerance (Bennett et al., 
2001;Brunkow et al., 2001;Wildin et al., 2001) and their involvement in impairment of 
effective immunity against certain pathogens (Boettler et al., 2005;Weiss et al., 2004) and 
some types of tumors (Curiel et al., 2004;Nishikawa and Sakaguchi, 2010), therapeutic 
strategies aimed to modulate their development and function may be beneficial for the 
treatment of a variety of immune-related diseases. Thus, therapeutic interventions that impair 
the function and/or reduce the number of distinct Tregs may favor initiation of immune 
responses towards cancer and chronic infections. Conversely, immunotherapies leading to 
increased number and/or elevated suppressive function of Tregs may be useful for the 
management of abnormal or excessive immune responses, such as various autoimmune 
diseases and chronic inflammatory diseases including asthma and inflammatory bowel 
diseases (Miyara et al., 2009). Moreover, the latter therapeutic approach may also potentially 
prevent graft rejection (Trzonkowski et al., 2009;Waldmann et al., 2006) and increase 
maternal tolerance against the fetus (Guerin et al., 2009;Saito et al., 2007). Critical in the 
design of an efficient strategy is to tip the balance towards either heightened Treg or effector 
T cell activity, depending on the character of the immune dysfunction (Miyara and Sakaguchi, 
2011). Accordingly, dominance towards Tregs is required in order to suppress ongoing 
pathological immune responses and induce tolerance to self-reactive effector T cells, whereas 
relative dominance of effector T cells is warranted to enhance or strengthen immune 
responses against tumors and some types of pathogens that have the potential to cause chronic 
infections. Thus, from a clinical point of view it might be desirable to control these T cell 
subsets disparately. 
Although Treg-based cellular therapy involving ex-vivo expansion of antigen-specific Tregs 
is an area of extensive research, there are still many issues that have to be addressed before it 
is safe to use cell-based therapies with expanded Tregs in the clinic (Miyara and Sakaguchi, 
2011;Sakaguchi et al., 2010). The challenges include successful expansion of a pure Treg 
population (as human FOXP3+ T cells comprise a heterogeneous population), maintenance of 
functional properties during in vitro expansion and not least stability in vivo after infusion. It 
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is still an open question whether this approach will be effective and introduce long-lasting 
effect. For this reason therapeutic interventions with small molecules or biological that 
selectively modulate or reprogram the function of Tregs in vivo may be an easier way forward 
and have clinical applicability. A global inhibition of Tregs is not desirable as this may 
increase the risk for initiation of autoimmune diseases. Consequently, antigen-specific Treg-
based therapies are warranted. The results reported in Paper II indicate a selective Erk 
signaling response in rTregs versus actTregs, an effect also observed between naive and 
effector/memory T cells. Inhibition of Erk may therefore not only influence conversion of 
rTregs to actTregs, but also inhibit activation of naive T cells and initiation of primary 
immune responses. Consequently, Mek and Erk merits further investigation for their potential 
as therapeutic targets for controlling various immune-related diseases, particularly those 
involving excessive activity of Tregs. 
4.3 PAG regulation of early BCR signaling 
Accumulating data have demonstrated that PAG functions as a negative regulator of proximal 
TCR-signaling and thereby participates in fine-tuning the threshold for T cell activation. This 
effect has been attributed to the ability of PAG to bring Csk into the proximity of activated 
SFKs, allowing Csk to reduce the activity of the kinases that are concomitantly bound to the 
adaptor protein. In Paper III, we wanted to explore whether a similar functional role of PAG 
could be identified in B cells. Amongst the different B cell-expressed SFKs, Lyn appears to 
be the only one indispensable to B cell development and activation. We therefore decided to 
examine the interaction of this particular SFK with PAG in order to explore the regulatory 
role of PAG in early BCR signaling (Paper III). 
4.3.1 Formation of a Lyn/PAG signaling complex 
Mapping of the interactions between the SH3 domain of Lyn and PAG in Paper III revealed 
an ability of Lyn to bind to two proline-rich domains (PRDs) of the cytoplasmic portion of 
PAG, termed PRD1 and PRD2. The affinity for PRD1 appeared to be stronger than that 
observed for PRD2. Interestingly, Lyn-mediated phosphorylation of PAG seemed critically 
dependent on the interaction with the first PRD, as disruption of this binding site totally 
abrogated initiation of PAG phosphorylation. The observed ability of Lyn to associate with 
both PRDs in PAG contrasts with earlier observations by Ingley et al., which suggested 
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involvement of only one motif, specifically PRD2, for the preliminary formation of a 
Lyn/PAG signaling complex. It should be noted, though, that these data were obtained in a 
preliminary yeast two-hybrid screen (Ingley et al., 2006). However, an ability of SKFs to 
interact with PAG via several distinct binding domains of the same character is supported by 
Oneyama et al., who demonstrate that PAG-mediated c-Src transformation is dependent on 
two independent SH2 binding sites (Oneyama et al., 2008). 
Although the binding of Lyn to PRD2 in our study did not appear to be crucial for the initial 
phosphorylation of the adaptor protein itself, our data do not exclude a functional role of this 
binding in vivo. It is possible that this interaction enhances the phosphorylation of PAG that is 
initiated upon binding to PRD1 or it could cooperate with other signaling molecules that 
direct other functional outcomes. Another interesting possibility would be if the second PRD 
of PAG confers binding to another SH3 domain-containing molecule such as PI3K, which has 
been shown to differ slightly from Lyn with respect to PRD binding preferences (Rickles et 
al., 1994). Indeed, recent data published by Tauzin et al. indicate that PI3K may bind directly 
to phosphorylated PAG in some B lymphoma cell lines (Tauzin et al., 2011). Based on the 
fact that B cells express several SFKs, it is reasonable to assume that PAG through Csk could 
contribute to regulating B cell activation by modulating their activities as well. Our finding 
that Fyn co-immunoprecipitated with PAG in lysates from the B lymphoma cell line Raji is in 
line with this notion and supports earlier reports that have suggested a general SFK-
associating capacity of PAG (Ingley, 2008). 
4.3.2 The role of PAG in early BCR signaling 
Data from earlier reports indicate a differential role of PAG in the activation of B- and T cells 
as an elevated phosphorylation level of PAG is observed upon triggering of the BCR, whereas 
the adaptor becomes transiently dephosphorylated by TCR stimulation (Awasthi-Kalia et al., 
2001;Brdicka et al., 2000;Kawabuchi et al., 2000;Mutch et al., 2007). Despite these 
differences, our results in Paper III indicate that PAG negatively regulates antigen-induced 
signaling responses in B cells. This effect was observed in primary human B cells and the 
normal EBV-transformed B cell line Con. In contrast, no regulatory role of PAG in BCR 
signaling was detectable in the Raji line of human Burkitt’s lymphoma (BL) B cells, which 
appeared to express excessive amounts of PAG in our study. Taken together, these 
observations suggest that PAG potentially may exert different functional roles in normal B 
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cells versus B lymphoma cell lines, an issue that is discussed in detail in the following 
section. 
In our study, transient elevation of PAG resulted in decreased responses of early BCR 
signaling in Con cells. Moreover, increasing the interaction of Lyn with the adaptor using a 
PAG construct with improved affinity for Lyn further enhanced the inhibitory effect of PAG. 
In contrast, abrogation of Csk binding to PAG, by transient overexpression of a PAG 
construct lacking Csk binding sites, led to augmented BCR signaling. Accordingly, our data 
demonstrate a PAG-mediated BCR inhibitory role of Lyn and Csk in the normal B cell line 
Con. However, to which extent the inhibitory effects of the Lyn/PAG signaling complex may 
be transferred to primary human B cells remains unknown. Based on the fact that PAG is an 
adaptor protein with dual function, having the ability to control signaling processes by either 
regulating the activity of Csk or sequestering signaling mediators in lipid rafts, it is possible 
that it mediates its function in primary human B cells by localizing Lyn in the proximity of 
stimulated BCRs, thereby regulating the function of other signaling molecules. Consistent 
with this idea, activated Lyn has been demonstrated to rapidly phosphorylate tyrosine residues 
of the inhibitory BCR coreceptor CD22 following stimulation of membrane-associated IgMs 
(Chan et al., 1997;Leprince et al., 1993;Nitschke, 2005). As noted in the Introduction, CD22 
has the ability to negatively modulate BCR signaling upon induced phosphorylation of its 
ITIM sequences. These phosphorylated ITIMs will recruit intracellular signaling proteins 
such as the tyrosine phosphatase SHP1, resulting in down-regulation of BCR signals 
(Nitschke, 2005). Since PAG may influence both the CD22 and BCR receptors through either 
ITAM or ITIM sequences, the final outcome of increased PAG phosphorylation upon BCR 
stimulation depends on the local distribution of these around the phosphorylated adaptor 
protein. Phospho-flow analysis of the signaling motifs involved could potentially provide 
further insight into the function of PAG in B cell activation. For the time being, however, 
phospho-flow antibodies that detect these motifs remain commercially unavailable, and such 
analyses were therefore precluded from the study presented in Paper III. 
The observations that PAG knockout mice, in contrast to Csk knockout mice (Imamoto and 
Soriano, 1993), are viable (Dobenecker et al., 2005;Xu et al., 2005) and that Csk is recruited 
to the plasma membrane even in the absence of PAG (Dobenecker et al., 2005;Xu et al., 
2005) imply that other membrane-bound Csk adaptor proteins may exist. In support of this, a 
recent study demonstrated that the membrane adaptor protein Caveolin-1 cooperates with 
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PAG in coordinating Csk-mediated inhibition of c-Src in fibroblasts and lung cells from mice 
(Place et al., 2011). It was found that depletion or functional inactivation of one of these two 
adaptors led to up-regulation or elevated phosphorylation of the other so as to ensure 
sufficient recruitment of Csk and thereby maintain normal c-Src activity. Furthermore, 
elevation of c-Src activity upon simultaneous removal of both of these Csk adaptor proteins, 
by a combination of knockout and knockdown, indicated that these two proteins were the only 
Csk adaptors available in the studied cell system (Place et al., 2011). Together these findings 
may explain why knockout of Csk in mice was fatal (Imamoto and Soriano, 1993) whereas 
removal of either Caveolin-1 (Murata et al., 2007) or PAG (Dobenecker et al., 2005;Xu et al., 
2005) did not affect viability. Analysis of the overall tyrosine phosphorylation responses in 
murine PAG-/- T cells revealed that these cells responded normally upon activation 
(Dobenecker et al., 2005;Xu et al., 2005), again indicating that compensatory mechanisms are 
brought into play in these cells upon removal of PAG. 
Redundancy between other B cell-expressed GEM-associated TRAP members such as 
NTAL/LAB and LIME may have contributed to the apparent minor changes observed in BCR 
signaling upon PAG-KD in Paper III. Whether these two TRAPs play an inhibitory role in B 
cell activation is a matter of controversy (Simeoni et al., 2008) and further investigations are 
required for addressing the relative contribution of PAG and other adaptor proteins in B cell 
activation. 
4.3.3 Function of PAG in normal B cells versus B lymphoma lines 
The observations that PAG can be both down-regulated and up-regulated in transformed cells 
(Feng et al., 2009;Kanou et al., 2011;Oneyama et al., 2008;Sirvent et al., 2010;Svec et al., 
2005;Tauzin et al., 2008) suggest that PAG might exert dual regulatory functions in cell 
activation. Particularly, PAG has been found to be highly expressed in Burkitt’s lymphoma 
and other lymphoma variants (Svec et al., 2005;Tauzin et al., 2008). A similar expression 
level was observed in kidney cancer (Feng et al., 2009). Under these circumstances it might 
be that PAG enhances cell activation either directly by interacting with SFKs or indirectly by 
organizing several signaling mediators in a membrane-associated signaling complex. The 
latter is confirmed by a recent publication by Tauzin et al., which demonstrates that activated 
Lyn/PAG signalosomes in some B lymphoma cell lines including Raji cells organize a set of 
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signaling molecules that appear to be crucial for the generation of survival signals (Tauzin et 
al., 2011). 
In Paper III, we compared early BCR signaling responses between primary human B cells and 
immortalized, EBV-transformed Con and Raji cells. The expression levels of PAG in the 
EBV-positive, BL-derived Raji cells were significantly higher than those observed for 
primary B cells and the normal transformed Con line. Despite lower expression of PAG, 
however, primary B cells appeared to contain more Lyn than the transformed cells. A similar 
inverse relationship between the expression levels of Lyn and PAG has earlier been reported 
(Ingley et al., 2006). Nevertheless, in line with previous work published by Ke et al. (Ke et 
al., 2009), the kinase activity was found to be higher in the transformed cell lines. In 
summary, we observed that the kinase/adaptor ratio varied the most between primary B cells 
and transformed cells, indicating that PAG could potentially exert different functions in 
normal versus immortalized B cell lines. We studied these differences in terms of early BCR 
signaling. 
Our data demonstrated that phosphorylation of the proximal signaling molecules SYK, 
BLNK, Btk and PLC2 were increased in primary B cells compared to transformed cell lines, 
possibly due to the fact that primary B cells were in a resting state whereas the cell lines were 
highly activated even at the outset of the experiment (Gururajan et al., 2006). SYK has 
previously been found to be constitutively active in B lymphoma cells (Chen et al., 
2008;Gururajan et al., 2007) and specifically to be important for the survival of Raji cells 
(Tauzin et al., 2011). We observed some differences in signaling between Con and Raji cells 
with respect to these proximal mediators, but our data do not allow us to draw any conclusion 
regarding the involvement of PAG in these differences. 
The phosphorylation of Akt in response to IgM cross-linking in the presence of H2O2 
appeared to be higher and more sustained in the B cell lines compared to the primary B cells. 
This observation is in agreement with earlier findings that activated Akt promotes tumor 
survival through both anti-apoptotic and pro-proliferative effects that are utilized by a range 
of human cancer cells (Osaki et al., 2004;Nicholson and Anderson, 2002;Marone et al., 2008). 
Although the expression level of Lyn was markedly lower in transformed cells the kinase 
activity in these cells appeared to be higher. Lyn has previously been linked to the activation 
of the PI3K/Akt pathway in lipid rafts, resulting in the induction of small cell lung carcinoma 
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(Arcaro et al., 2007), colorectal carcinoma (Sirvent et al., 2010), chronic lymphoid leukemia 
(Contri et al., 2005) and acute myeloid leukemia (Dos et al., 2008). 
To explore whether the differences in signaling responses observed between Con and Raji 
cells were due to PAG, we did siRNA KD of PAG in the Raji cells. However, we were unable 
to detect any changes in signaling events by knocking down PAG as measured by 
phosphorylation of proximal signaling mediators, phospho-Erk and intracellular calcium flux. 
It might be that the stimulatory conditions used in our setup were inappropriate for elucidating 
the functional role of PAG in the transformed cells. Despite repeated attempts with various 
RNAi strategies, we were only able to knock down about 50% of the amount of PAG in the 
Raji cell line, which could explain why were unable to detect any changes in PAG-dependent 
signaling response in PAG-KD Raji cells. 
4.4 Experimental tools for signaling studies 
The study of signal transduction in smaller subsets of cells using traditional biochemical 
methods has always been challenging. However, recent technical developments including 
fluorescent cell barcoding (FCB) (Krutzik and Nolan, 2006) and a growing number of 
phospho-epitope-specific antibodies have made it possible to use phospho-specific flow 
cytometry to study signaling processes at single-cell resolution in several phenotypically 
defined immune cell populations simultaneously (Kalland et al., 2011;Krutzik and Nolan, 
2003;Krutzik et al., 2004;Oberprieler et al., 2010;Perez and Nolan, 2002). Moreover, these 
developments have enabled increasing the resolution to a level where signaling differences 
can be linked to functional properties in small subsets of cells as shown in Paper II (Kalland 
et al., 2011). For the three studies included in this Thesis, a phospho-flow technique was used 
as a tool for investigation. I will therefore compare this technique with three other methods, 
where one of these, immunoblotting, currently is regarded as the primary tool for examination 
of signal transduction in various immune cell populations. 
4.4.1 Phospho-epitope-specific flow cytometry 
The signaling processes originating at surface-bound receptors are highly regulated by post-
translational phosphorylation events, conferring changes in terms of biological activity, 
positioning or ability to interact with other proteins. Phospho-flow is a phospho-epitope-
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specific intracellular staining technique for flow cytometry that allows for examination of 
phosphorylation cascades in heterogeneous cell types at the level of single cells (Irish et al., 
2006b;Krutzik and Nolan, 2003;Krutzik et al., 2004;Perez and Nolan, 2002). Thus, by 
measuring protein phosphorylation with phospho-specific antibodies in different immune 
cells, defined by distinct phenotype markers, we get an insight into the temporary dynamics of 
multiple phospho-sites under various experimental conditions. As we experienced while 
establishing the phospho-flow protocol applied to the studies included in this Thesis, and 
which is also reported by the group of Garry Nolan (Schulz et al., 2007), careful titration of 
antibodies directed against both the phospho-epitopes and the phenotype markers is essential 
for a successful analysis of the signaling nodes in the intended subsets of cells. Therefore, 
each antibody implemented in our studies was first tested for suitability with respect to our 
protocol, then titrated to identify the concentration that would simultaneously maximize the 
fluorescence intensity shift, achieve minimal background stain, minimize antibody-
consumption and ensure staining reliability. 
The specificity and sensitivity of phospho-specific antibodies against TCR-activated proteins 
such as the MAPKs (Erk, p38 and SAPK/JNK) and Akt, implemented in phospho-flow 
cytometric methods, had been validated by use of specific inhibitors and parallel Western blot 
analysis in previous studies (Perez and Nolan, 2002). Furthermore, antibodies specific for 
pStat3, pSYK/ZAP70, pNF-B, pBtk and pPLC2 had also been widely used previously in 
studies for intracellular staining (Bendall et al., 2011;Gibbs, Jr. et al., 2011;Irish et al., 
2004;Irish et al., 2006a;Irish et al., 2010;Krutzik and Nolan, 2003;Krutzik et al., 2004;Krutzik 
et al., 2008). Following our standard calibration setup for signaling studies in T cell, each 
antibody was tested for their concentration-response in freshly isolated T cells treated with 
pS/T kinase inhibitors (Calyculin A), pY kinase inhibitors (Na3VO4), physiological CD3 and 
CD28 antibodies, anisomycin, and the combined use of the PKC activator phorbol 12-
myristate 13-acetate (PMA) and the intracellular calcium inducer ionomycin (I), as partly 
demonstrated in Figure 11 and Figure S5 in the supplementary of Paper I. The phospho-flow 
results from these calibration experiments where either compared with western blot (WB) 
analyses of the same sample and/or benchmarked against signaling patterns reported in earlier 
studies. 
In order to increase the capacity of phospho-flow based methods, the group of Garry Nolan 
has developed another advanced cytometric technique called fluorescent cell barcoding (FCB) 
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(Krutzik and Nolan, 2006) that we made use of. Particularly, FCB encompasses the use of 
varying concentrations of bioreactive fluorescent dyes (FCB markers), staining cells that are 
treated differently with different intensities (Figure 11). 
Figure 11. Flow diagram of the experimental 
setup using the phospho-flow technique in 
combination with FCB. The four samples were 
treated as follows (from the left): unstimulated 
(negative control); stimulated by the cross-linking 
of CD3 and CD28 Abs; treated with PMA and 
ionomycin (I); treated with anisomycin. After 
stimulation for a specific period of time, the cells 
were fixated in PFA in order to maintain their 
phosphorylation state. The fixated samples were 
then incubated with amine-reactive fluorescent 
dyes at varying concentrations for identification 
purposes. The samples were further permeabilized 
with ice-cold methanol, then washed, combined 
into one tube and stained with phospho-specific 
antibodies (pAb). During software analysis of the 
acquired data each of the original samples were 
identified according to their FCB signature and 
assessed separately with respect to each of the 
phospho-specific antibodies. In the representative 
FACS plot, each of the four different populations 
represent cells stimulated with one specific kind 
of stimulating agent, as noted above. The y-axis 
corresponds to the changes in phosphorylation of 
a specific epitope. Each column in the heatmap 
represents a different stimulus and each row 
represents a specific phospho-epitope. The color 
of each block is indicative of the fold change in 
mean fluorescence intensity in that channel. 
 
This provides each sample with a unique fluorescence signature, enabling the combination 
and analysis of several distinct cell-samples at the same time, thereby eliminating assay-to-
assay variation. The power of the FCB technique can be further enhanced by the use of two or 
more FCB reagents at the same time, generating a complex color signature that may be used 
to trace even more cell samples back to the sample from which they originated, on a per-cell 
basis. This technique has been taken advantage of throughout the present work, in particular 
in the studies reported in Paper I-II, and to some extent for the study reported in Paper III. 
Besides improving assay resolution, this technique also contributes to reducing antibody 
consumption and acquisition time. In multi-color phospho-flow analyses, multiple signaling 
nodes can be monitored simultaneously in a single cell using phospho-specific antibodies 
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labeled with distinct fluorophores. Hence, it is possible to obtain information on how the 
different signaling nodes interact in response to a given stimulus (Irish et al., 2004;Irish et al., 
2006b;Perez and Nolan, 2002). In any case, the number of variables that can be studied at the 
same time is primarily subject to limitations in the instrumentation, such as the number of 
detectors (PMTs) in the FACS analyzer, as well as in the availability of reagents with 
appropriate fluorophores. Importantly, the difficulty of the experiment increases with each 
additional parameter as the spectral overlaps, which require compensation, gets more 
complicated. 
In summary, phospho-flow is a semi-quantitative technique that provides relative 
quantification of the acquired data (Perez and Nolan, 2002). Its high throughput potential 
makes it a suitable tool for the investigation of complex signaling responses. 
4.4.2 Comparison of immunoblotting and phospho-flow cytometry 
Immune cell signaling, especially TCR signaling, has traditionally been studied using either 
immune-precipitation (pull-down) or immune-blotting techniques (e.g. WB). Our current 
knowledge on the signaling cascades initiated in response to TCR engagement is based 
heavily on results gained by the use of WB. While WB provides information on the 
phosphorylation of proteins in denatured cell lysates, phospho-flow allows for the detection of 
phosphorylated epitopes in cells that are fixed and permeabilized. 
As detergent-insoluble fractions are removed by centrifugation or separation from the liquid 
phase of the lysate, at least part of the phosphorylated proteins that associate with lipid raft or 
the cytoskeleton may be removed and therefore not detected by standard WB analysis. The 
phospho-flow technique, on the other hand, detects the phosphorylation status in samples of 
stimulated cells that are fixed with paraformaldehyde (PFA), which cause protein-protein 
cross-linking and therefore are assumed to preserve both the localization and the interaction 
with other binding-partners of the targeted phosphoproteins. For this reason, in contrast to 
WB, phospho-flow gives information also of phosphorylated proteins that resides in detergent 
insoluble fractions, e.g. lipid rafts or those that associate with the detergent insoluble 
cytoskeleton, which is the case for certain signaling molecules after activation of antigen 
receptors (Goldman et al., 1997;Edmonds and Ostergaard, 2002). It should be noted, however, 
that the cell preparation involved in the phospho-flow protocol may mask or transform the 
epitopes to which the detecting antibodies bind, or impair the access of the phospho-epitope-
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specific antibodies to their intracellular phosphorylated targets. Another caveat of this 
technique relies on the fact that access to the intracellular phospho-epitopes is gained by a 
methanol-based permeabilization that may cause some degree of protein denaturation. 
Generally, phospho-specific antibodies are verified by the manufacturers by their capacity to 
bind linear stretches of phosphorylated peptides. Thus, you can assume that the antibodies 
specifically made for phospho-flow cytometry will detect the fixed phospho-epitope while 
kept in its original state, as well as its denatured counterpart. The group of Garry Nolan has 
verified the specificity of several of the phospho-specific antibodies and designed an 
optimized phospho-flow protocol for these, comparing the results obtained by phospho-flow 
with WB results using the same cell samples (Krutzik and Nolan, 2003;Perez and Nolan, 
2002). Both of these methods provided similar qualitative signaling patterns for pErk, pp38, 
pJNK, pStat1, pStat5 and pStat6, indicating that the results obtained by either method are 
equal for the phospho-specific antibodies tested (Krutzik and Nolan, 2003). Accordingly, in 
Paper III, we verified the antibodies specific for pBtk, pSYK, pBLNK and pErk in the context 
of PAG KD in normal B cells. However, based on the differences in the two experimental 
procedures as mentioned above, these methods may well yield different signaling patterns in 
response to the same stimulatory conditions, as described by Haas and colleagues (Haas et al., 
2008). Interestingly, in this study, they demonstrated a gain in sensitivity for their phospho-
flow approach compared to their WB analysis, phospho-flow revealing both concentration- 
and time-dependent changes dependent on the stimulatory conditions that was not even 
detectable with standard WB analysis. 
One of the advantages of the phospho-flow technique over WB is its ability to analyze 
unsorted, complex mixtures of cells and its high-throughput potential, especially with the 
combined use of FCB as discussed in section 4.4.1. Of note, as reported by Perez et al. (Perez 
and Nolan, 2002), positive isolation of different cell populations may perturb the 
interpretation of the kinase activities of cells as antibodies used for the purpose of isolation 
upon binding can induce some sort of signaling itself. Hence, the permission of the phospho-
flow technique to analyze heterogeneous mixtures of cells without prior cell sorting excludes 
this type of signaling disturbance. Furthermore, as FCB allows for the inclusion of both 
positive and negative controls in the same sample, pipetting and staining errors may be 
eliminated. For these reasons, phospho-flow represents an improvement over WB for studies 
of signal transduction that may also be beneficial in high-throughput setups for the discovery 
of new drugs in predefined populations of immune cells. 
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Although phospho-flow offers several advantages over WB analysis, some situations warrant 
the continued use of WB. Notably, while WB identifies proteins based on their molecular 
weight, phospho-flow does not. Hence, WB yields additional information about the mass of 
the phosphoproteins detected and thereby an indication of the specificity of the phospho-
specific antibodies applied in the setup. Moreover, as WB is performed on cell lysates, the 
cell samples may be subjected to subcellular fractionation first, enabling the analysis of the 
subcellular localization of the phospho-proteins as well. These are all important points to bear 
in mind while selecting the most appropriate technique for a particular experimental setup. 
4.4.3 Mass spectrometry (MS) 
In principle, any soluble protein can be analyzed by MS. The main advantage with this 
approach is the unbiased and accurate characterization of proteins that relies on determination 
of peptide masses and identification of their sequences, which generally is performed by 
tandem MS (MS2) (Germain et al., 2011). Still, as a tool for analyses of signaling networks 
MS suffer some weaknesses. One of these is low throughput. Sample preparations for MS 
analyses typically require extensive preprocessing, and both gradient separations by 
chromatography and data analysis are time-consuming processes. For system views in 
immunology an important disadvantage is the necessity of abundant starting material; for T 
cells that contain a small cytoplasmic volume, a cell number of at least 107 is often required. 
Furthermore, only a fraction of the sample is analyzed in one MS run, especially in complex 
samples, and there is a risk of assessing only the most abundant peptides (Germain et al., 
2011). Thus, many peptides will go waste during the analysis and never be identified. For this 
reason, examination of samples run in parallel will give slightly different results as the 
sampling in each run will be incomplete. In order to achieve isolation of the less abundant 
phosphopeptides in a phosphoproteomic setup, enrichment techniques are utilized. In Paper I, 
we applied TiO2 affinity chromatography to this end. Importantly, recent progress in MS 
instrumentation and technology has led to the emergence of high-sensitivity quantitative MS 
techniques that can be used on fewer cells (Luber et al., 2010;Iwai et al., 2010). Thus, while 
MS analyses had previously been performed predominantly on materials from cultured cells, 
it was now feasible to analyze primary cells, as had been done in Paper I. The major strength 
of MS with respect to phosphoproteomic analyses is that it allows for identification and 
comparison of thousands of proteins and phospho-sites in one run independently of antibody 
specificities. However, as opposed to phospho-flow cytometry that allow analysis of single-
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cells, measurements from MS analyses, as those from WB analyses, reflects only averaging 
effects of the whole cell population analyzed. 
4.4.4 Microscope techniques 
Although phospho-flow cytometric approaches are valuable for analyses of phosphorylation-
based signaling responses in primary immune cells, they are not able to provide information 
about localization, translocation or localized up- or down-regulation of the labeled phospho-
sites over time. Despite the capability to analyze suspensions of heterogeneous cell 
populations, examination of cells located in a tissue environment is not possible. Furthermore, 
signaling responses detected by phospho-flow cytometry cannot directly be associated with 
cell behavior (e.g., changes in size, morphology, cell dynamic and motility). In cases where 
the above mentioned aspects are desirable to study, microscopic imaging is the preferred tool 
for investigation (Germain et al., 2011). As microscopic methods have not been utilized in the 
studies presented in this Thesis, further details about these methods will not be presented here. 
However, Sarris and Betz have reviewed the topic and provide an overview of the imaging 
techniques that have been applied in immunological research (Sarris and Betz, 2009). Of note, 
analyses of kinase-dependent intracellular signaling responses may be analyzed by a real-time 
FRET (fluorescence resonance energy transfer)-based imaging approach that relies on 
genetically encoded fluorescent indicators called Phocuses (fluorescence indicators for protein 
phosphorylation processes that can be custom-made), tracing phosphorylation-based 
alterations (Sato et al., 2002). In contrast to phospho-flow cytometry, this approach enables 
visualization and subcellular localization of intracellular phosphorylation processes using a 
confocal laser-scanning microscope. As a result, this method provides information not only of 
temporal but also of spatial dynamic changes of phosphorylation-dependent signaling at the 
single-cell level. Thus far, however, it is not possible to measure several kinases at the same 
time. 
4.5 Closing comments and future perspectives 
In the present Thesis, we have investigated phosphorylation-based signal integration in human 
immune cells. Signaling studies in T cells have previously demonstrated that approaching the 
cell from a systems perspective may be a prerequisite for understanding the functional 
implications of individual signaling processes. Notably, signaling responses may occur but 
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have no actual consequence. Therefore, although we examined the functional outcomes 
associated with the signaling responses observed in rTregs upon activation, further analyses 
of cellular behaviors linked to the signaling responses reported in Paper I-III would be 
beneficial. For instance, does the high basal level of PKA signaling in effector/memory T 
cells impair proliferation or cytokine production upon stimulation, or does their high 
constitutive PKA signaling and phopho-Erk levels enhance their responsiveness to true 
antigenic stimulation? Is the production of Igs enhanced upon PAG-KD or do the B cells 
become unresponsive? Given our in-depth data, the challenge now would be to assign a 
function to each of the signaling nodes observed. At present, many studies deduce novel 
biological mechanisms but do not validate them. Nevertheless, elucidation of these 
mechanisms will be essential in order to design modulation strategies for the generation and 
function of adaptive immune cells in the development of vaccines or therapeutics for the 
treatment of immunological diseases such as chronic infections, autoimmunity and cancers. 
The work presented in Paper II led to a pending patent application on methods to inhibit 
activation of rTreg in a Mek-Erk-dependent manner, filed by the University of Oslo 
Technology Transfer Office, Inven2 AS. Future research should therefore reveal additional 
details surrounding the Mek-Erk-mediated inhibition of rTregs and will probably identify its 
potential in various clinical applications. This work is currently in progress in the laboratory 
of Prof. Kjetil Taskén, where several Mek-inhibitors have already been investigated (Lieske 
& Tasken, unpublished data). In addition, further investigation regarding the different 
signaling processes induced upon triggering of the CD28- and CD2 coreceptors are 
warranted, as these molecules influence the final outcome of T cell-mediated immunity. In 
this respect, a central issue introduced in the discussion is how CD2 compensates for its 
incapacity to properly activate NF-B if the hypothesis of redundancy is correct. Further, a 
more detailed understanding of the mechanisms by which CD2 functions as a coreceptor in T 
cell activation will promote a clearer characterization of the interplay between antigen-
recognition and CD28- and CD2 triggering in the initiation of T cell-mediated immune 
responses. Presently, the relative contribution of CD28- and CD2 costimulation in activated 
naive and effector/memory T cells is investigated in more depth in the laboratory of Prof. 
Kjetil Taskén (Skånland et al., manuscript in preparation). The PGE2 signaling map obtained 
from the work presented in Paper I may serve as background information for studies of 
aberrant signaling responses to PGE2 in immune-related diseases. The laboratory of Prof. 
Kjetil Taskén is at present using this study as a basis for studies designed to reveal signaling 
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differences between healthy individuals and patients with colorectal cancers (Moltu et al., 
unpublished data). Finally, the relative contribution of PAG and its cooperation with other 
adaptor proteins in B cell activation would be interesting to address in a follow-up study in 
order to elucidate its exact function in the activation processes of both normal B cells and 
various B lymphoma lines. Based on the fact that PAG is over-expressed in various B 
lymphoma cells, it would be of great interest to determine the impact of PAG on the aberrant 
signaling responses in these cells, as this eventually may lead to the identification of 
therapeutic targets for the treatment of these cancer types. As functional outcomes are 
expected to be dependent on the characteristics of the cells, detailed characterization of the 
studied tumor cells will be of importance in order to avoid misinterpretation of data. For 
future studies of the functional roles of PAG in lymphoma cells, it would be warranted to 
properly characterize the cells in order to decide whether the testing strategies or endpoints 
are appropriate for the indented purpose of the study. 
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5 Conclusions 
1. 247 phosphorylation sites on 207 different proteins were found to be regulated by PGE2 in 
primary T cells by means of a quantitative MS-based approach. Many of these were 
previously unknown phosphorylation sites (Paper I). 
2. Based on the MS data, kinase pathway prediction and phospho-flow network analyses, 
PKA was identified as the central node of PGE2-regulated signaling networks in primary 
human T cells (Paper I). 
3. A constitutively active PKA signaling node was identified in effector/memory T cells 
(Paper I). 
4. Engagement of the CD28 coreceptor was found to produce unique signals essential for 
NF-B activation, whereas CD2 costimulation enhanced TCR-mediated signaling 
responses (Paper II). 
5. CD28 costimulation potentiated TCR signaling in both naive and effector/memory CD4+ 
and CD8+ T cells and the signaling responses were further enhanced by concomitant 
stimulation through the CD2 coreceptor (Paper II). 
6. Augmented constitutive phospho-Erk levels were identified in effector/memory T cells 
(Paper II). 
7. Differences in signaling between rTregs and actTregs were identified. Whereas activation-
induced Akt signaling was present in rTregs and diminished in actTregs, actTregs 
displayed constitutively high Erk phosphorylation with resulting diminished Erk 
responses compared to rTregs (Paper II). 
8. A Mek-Erk-dependent induction of FOXP3 was found to be crucial for the development 
of rTregs into fully competent actTregs (Paper II). 
9. Lyn was demonstrated to associate through its SH3 domain with two PRDs of PAG. The 
affinity for PRD1 was stronger than that observed for PRD2 and binding to PRD1 
appeared to be essential for initiating PAG phosphorylation (Paper III). 
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10. PAG, by means of Lyn and Csk, negatively regulates proximal BCR signaling in normal 
human B cells, but not in the B lymphoma line Raji with over-expressed PAG (Paper III). 
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